STOCK TITAN

Tenon Medical Q3 2026 net loss widens to $6.64M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Tenon Medical, Inc. (TNON) reported third-quarter 2026 revenue of $1.432 million, versus $1.173 million a year earlier, and a net loss of $6.639 million, versus $3.339 million. For the nine months, revenue was $4.090 million versus $2.463 million, while net loss was $14.165 million versus $9.724 million.

Cash and cash equivalents were $8.271 million as of September 30, 2026, compared with $3.756 million as of December 31, 2025; operating activities used $8.106 million in cash during the nine-month period. Management said substantial doubt exists about Tenon’s ability to continue as a going concern and that September 30 cash would not be sufficient to meet obligations for at least 12 months from issuance of the financial statements. Tenon repaid its convertible notes in full through prepayments totaling $5.126 million in August and September.

Tenon reported FDA 510(k) clearance for its Catamaran SI Joint Fusion System and the September 30 commercial launch of its SImmetry+ titanium 3D-printed lateral screw; alpha-launch revenue was approximately $1.2 million from late 2025 through the third quarter of 2026. On October 16, Tenon expanded its at-the-market program to up to $7.176 million in aggregate offering price, excluding $2.809 million previously sold.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month revenue was $4.090 million, versus $2.463 million in 2025.

Negative

  • Major pointNine-month net loss was $14.165 million, versus $9.724 million in 2025.
  • Major pointGoing-concern disclosure cites substantial doubt for one year after statement issuance.

Filing Explained

On October 16, the investor in the August private placement waived restrictions that had limited Tenon’s ATM expansion; in exchange, Tenon issued it a warrant for up to 125,000 common shares at $5.02 each, creating potential dilution if exercised. Tenon also agreed to file a resale registration statement within 60 days.

Third-quarter revenue $1.432 million Three months ended September 30, 2026; $1.173 million in 2025.
Third-quarter net loss $6.639 million loss Three months ended September 30, 2026; $3.339 million loss in 2025.
Nine-month revenue $4.090 million Nine months ended September 30, 2026; $2.463 million in 2025.
Nine-month net loss $14.165 million loss Nine months ended September 30, 2026; $9.724 million loss in 2025.
Cash and cash equivalents $8.271 million As of September 30, 2026; $3.756 million as of December 31, 2025.
Operating cash used $8.106 million Nine months ended September 30, 2026.
At-the-market program aggregate offering price Up to $7.176 million Amount eligible for sale after the October 16, 2026 prospectus supplement; excludes $2.809 million previously sold.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
at-the-market offering financial
"establish an at-the-market offering program"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
pre-funded warrants financial
"pre-funded warrants to purchase up to an aggregate"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
derivative liability financial
"accounted for as an embedded derivative liability"
A derivative liability is an obligation a company owes because of a derivatives contract—such as an option, future, swap, or forward—that has moved against it and now has negative value. Think of it like a settled bet that turned into a bill: if market moves go the other way, the company may have to pay cash or deliver assets. Investors care because these liabilities can create sudden losses, add leverage or counterparty risk, and change a company’s true financial exposure beyond its everyday operations.
Level 3 fair value measurement financial
"classified as a Level 3 fair value measurement"
anti-dilutive financial
"potential common stock equivalents is anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was TNON’s revenue in the third quarter of 2026?

TNON reported $1.432 million in revenue for the three months ended September 30, 2026, compared with $1.173 million for the same period in 2025. For the nine months ended September 30, revenue was $4.090 million in 2026 and $2.463 million in 2025.

What warrant did Tenon issue in its October 2026 investor waiver?

On October 16, 2026, Tenon issued the investor a Series B common stock purchase warrant for up to 125,000 shares, with an exercise price of $5.02 per share and an expiration date of September 14, 2031. The warrant is subject to beneficial ownership limitations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 0001560293 --12-31 1 0001560293 2026-07-01 2026-09-30 0001560293 us-gaap:SubsequentEventMember 2026-10-16 2026-10-16 0001560293 us-gaap:SubsequentEventMember us-gaap:CommonStockMember us-gaap:WarrantMember 2026-10-16 0001560293 us-gaap:SubsequentEventMember us-gaap:IPOMember tnon:PreFundedWarrantsMember 2026-10-16 0001560293 2026-01-01 2026-09-30 0001560293 2025-01-01 2025-09-30 0001560293 2025-07-01 2025-09-30 0001560293 2026-09-30 0001560293 2025-12-31 0001560293 tnon:TerminationAgreementMember 2026-01-01 2026-09-30 0001560293 tnon:TerminationAgreementMember 2022-10-01 2022-12-31 0001560293 tnon:TerminationAgreementMember us-gaap:FairValueInputsLevel3Member 2022-10-01 2022-12-31 0001560293 tnon:TerminationAgreementMember 2022-10-06 2022-10-06 0001560293 tnon:TerminationAgreementMember 2022-10-06 0001560293 tnon:TerminationAgreementMember country:US 2022-10-06 0001560293 tnon:SalesRepresentativeAgreementMember 2026-09-30 0001560293 tnon:SalesRepresentativeAgreementMember 2022-04-30 0001560293 tnon:SalesRepresentativeAgreementMember 2021-10-31 0001560293 tnon:AmendedAndRestatedExclusiveSalesRepresentativeAgreementMember 2021-05-31 2021-05-31 0001560293 tnon:SalesRepresentativeAgreementMember 2021-05-31 2021-05-31 0001560293 tnon:SalesRepresentativeAgreementMember 2021-05-31 0001560293 tnon:SalesRepresentativeAgreementMember 2023-04-27 2023-04-27 0001560293 tnon:SalesRepresentativeAgreementMember 2020-04-01 2020-04-30 0001560293 tnon:SeriesAWarrantLiabilityMember 2026-01-01 2026-09-30 0001560293 tnon:SeriesAWarrantLiabilityMember 2026-07-01 2026-09-30 0001560293 tnon:SeriesAWarrantLiabilityMember 2026-09-30 0001560293 tnon:SeriesAWarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001560293 tnon:SeriesAWarrantLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-09-30 0001560293 tnon:SeriesAWarrantLiabilityMember us-gaap:MeasurementInputOptionVolatilityMember 2026-09-30 0001560293 tnon:SeriesAWarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001560293 2026-08-31 0001560293 us-gaap:WarrantMember 2026-08-31 2026-08-31 0001560293 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001560293 us-gaap:WarrantMember 2026-08-31 0001560293 2026-08-10 2026-08-10 0001560293 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember 2026-09-30 0001560293 us-gaap:WarrantMember us-gaap:MeasurementInputOptionVolatilityMember 2026-09-30 0001560293 us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001560293 2026-08-10 0001560293 us-gaap:WarrantMember 2026-07-01 0001560293 us-gaap:WarrantMember 2026-07-01 2026-07-01 0001560293 us-gaap:DerivativeMember 2026-01-01 2026-09-30 0001560293 srt:MinimumMember 2026-01-01 2026-09-30 0001560293 srt:MaximumMember 2026-07-01 2026-09-30 0001560293 srt:MaximumMember 2026-01-01 2026-09-30 0001560293 tnon:SeriesBNewWarrantsMember 2026-01-01 2026-09-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:SeriesBNewWarrantsMember 2026-09-14 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:SeriesBNewWarrantsMember 2026-09-14 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:SeriesBNewWarrantsMember 2026-09-14 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:SeriesBNewWarrantsMember 2026-09-14 0001560293 tnon:SeriesBNewWarrantsMember 2026-09-14 2026-09-14 0001560293 tnon:SeriesBNewWarrantsMember 2026-09-14 0001560293 tnon:SeriesAWarrantsMember 2026-09-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:SeriesAWarrantsMember 2026-08-31 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:SeriesAWarrantsMember 2026-08-31 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:SeriesAWarrantsMember 2026-08-31 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:SeriesAWarrantsMember 2026-08-31 0001560293 tnon:SeriesAWarrantsMember 2026-08-31 2026-08-31 0001560293 tnon:SeriesAWarrantsMember 2026-08-31 0001560293 tnon:JulyTwoThousandTwentySixWarrantsMember 2026-09-30 0001560293 tnon:JulyTwoThousandTwentySixWarrantsMember 2026-08-31 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:JulyTwoThousandTwentySixWarrantsMember 2026-07-01 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:JulyTwoThousandTwentySixWarrantsMember 2026-07-01 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:JulyTwoThousandTwentySixWarrantsMember 2026-07-01 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:JulyTwoThousandTwentySixWarrantsMember 2026-07-01 0001560293 tnon:JulyTwoThousandTwentySixWarrantsMember 2026-07-01 2026-07-01 0001560293 tnon:JulyTwoThousandTwentySixWarrantsMember 2026-07-01 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-11-11 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember 2025-11-11 0001560293 tnon:TwoThousandTwentyFiveSecuritiesPurchaseAgreementsMember us-gaap:MeasurementInputOptionVolatilityMember 2025-11-11 0001560293 tnon:TwoThousandTwentyFiveSecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember us-gaap:MeasurementInputExpectedTermMember 2025-11-11 0001560293 tnon:November2025WarrantsMember 2025-11-11 2025-11-11 0001560293 tnon:November2025WarrantsMember 2025-11-11 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:SeriesEWarrantsMember 2025-03-25 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:SeriesEWarrantsMember 2025-03-25 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:SeriesEWarrantsMember 2025-03-25 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:SeriesEWarrantsMember 2025-03-25 0001560293 tnon:SeriesEWarrantsMember 2025-03-25 2025-03-25 0001560293 tnon:SeriesEWarrantsMember 2025-03-25 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:SeriesDWarrantsMember 2025-03-25 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:SeriesDWarrantsMember 2025-03-25 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:SeriesDWarrantsMember 2025-03-25 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:SeriesDWarrantsMember 2025-03-25 0001560293 tnon:SeriesDWarrantsMember 2025-03-25 2025-03-25 0001560293 tnon:SeriesDWarrantsMember 2025-03-25 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:SeriesC2WarrantsMember 2026-09-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:SeriesC2WarrantsMember 2026-09-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:SeriesC2WarrantsMember 2026-09-30 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:SeriesC2WarrantsMember 2026-09-30 0001560293 tnon:SeriesC2WarrantsMember 2026-01-01 2026-09-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:SeriesC1WarrantsMember 2026-09-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:SeriesC1WarrantsMember 2026-09-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:SeriesC1WarrantsMember 2026-09-30 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:SeriesC1WarrantsMember 2026-09-30 0001560293 tnon:SeriesC1WarrantsMember 2026-01-01 2026-09-30 0001560293 tnon:SeriesCWarrantsMember 2025-03-11 2025-03-11 0001560293 tnon:SeriesC1WarrantsMember 2025-03-11 0001560293 tnon:SeriesC2WarrantsMember 2025-03-11 0001560293 tnon:SeriesBPreferredStockWarrantsMember 2024-09-05 2024-09-05 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:SeriesBPreferredStockWarrantsMember 2024-09-05 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:SeriesBPreferredStockWarrantsMember 2024-09-05 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:SeriesBPreferredStockWarrantsMember 2024-09-05 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:SeriesBPreferredStockWarrantsMember 2024-09-05 0001560293 us-gaap:CommonStockMember tnon:PurchaseAgreementMember 2024-09-05 0001560293 tnon:SeriesBPreferredStockWarrantsMember 2024-09-05 0001560293 tnon:SeriesAPreferredStockWarrantsMember 2024-02-20 2024-02-20 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:SeriesAPreferredStockWarrantsMember 2024-02-20 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:SeriesAPreferredStockWarrantsMember 2024-02-20 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:SeriesAPreferredStockWarrantsMember 2024-02-20 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:SeriesAPreferredStockWarrantsMember 2024-02-20 0001560293 tnon:SeriesAPreferredStockWarrantsMember 2024-02-20 0001560293 tnon:ConvertibleNoteWarrantsMember 2023-11-01 2023-11-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:ConvertibleNoteWarrantsMember 2023-11-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:ConvertibleNoteWarrantsMember 2023-11-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:ConvertibleNoteWarrantsMember 2023-11-30 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:ConvertibleNoteWarrantsMember 2023-11-30 0001560293 tnon:ConvertibleNoteWarrantsMember 2023-11-30 0001560293 tnon:RegisteredOfferingWarrantsMember 2026-09-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:RegisteredOfferingWarrantsMember 2023-06-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:RegisteredOfferingWarrantsMember 2023-06-30 0001560293 us-gaap:MeasurementInputExpectedTermMember tnon:RegisteredOfferingWarrantsMember 2023-06-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember 2023-06-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember 2023-06-30 0001560293 tnon:RegisteredOfferingWarrantsMember 2023-06-30 0001560293 tnon:RegisteredOfferingWarrantsMember 2023-06-01 2023-06-30 0001560293 2023-06-01 2023-06-30 0001560293 2023-07-16 0001560293 tnon:IPOWarrantsMember 2022-04-01 2022-04-30 0001560293 us-gaap:MeasurementInputRiskFreeInterestRateMember tnon:IPOWarrantsMember 2022-04-30 0001560293 us-gaap:MeasurementInputExpectedDividendRateMember tnon:IPOWarrantsMember 2022-04-30 0001560293 us-gaap:MeasurementInputOptionVolatilityMember tnon:IPOWarrantsMember 2022-04-30 0001560293 tnon:IPOWarrantsMember 2022-04-30 0001560293 tnon:TwoThousandAndTwentyTwoEquityIncentivePlanMember 2026-01-01 2026-09-30 0001560293 tnon:GeneralAndAdministrativeMember 2025-01-01 2025-09-30 0001560293 tnon:GeneralAndAdministrativeMember 2026-01-01 2026-09-30 0001560293 tnon:SalesAndMarketingMember 2025-07-01 2025-09-30 0001560293 tnon:SalesAndMarketingMember 2026-07-01 2026-09-30 0001560293 tnon:SalesAndMarketingMember 2025-01-01 2025-09-30 0001560293 tnon:SalesAndMarketingMember 2026-01-01 2026-09-30 0001560293 tnon:GeneralAndAdministrativeMember 2025-07-01 2025-09-30 0001560293 tnon:GeneralAndAdministrativeMember 2026-07-01 2026-09-30 0001560293 tnon:ResearchAndDevelopmentMember 2025-01-01 2025-09-30 0001560293 tnon:ResearchAndDevelopmentMember 2026-01-01 2026-09-30 0001560293 tnon:ResearchAndDevelopmentMember 2025-07-01 2025-09-30 0001560293 tnon:ResearchAndDevelopmentMember 2026-07-01 2026-09-30 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001560293 us-gaap:EmployeeStockOptionMember 2026-09-30 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001560293 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001560293 us-gaap:EmployeeStockOptionMember 2025-12-31 0001560293 tnon:TwoThousandTwentySixInducementAgreementMember 2026-09-11 2026-09-11 0001560293 tnon:TwoThousandTwentySixInducementAgreementMember 2026-09-11 0001560293 tnon:SeriesBNewWarrantsMember tnon:TwoThousandTwentySixInducementAgreementMember 2026-09-11 0001560293 tnon:SeriesAWarrantsMember tnon:TwoThousandTwentySixInducementAgreementMember 2026-09-11 0001560293 tnon:TwoThousandTwentySixPrivatePlacementOfferingMember 2026-01-01 2026-09-30 0001560293 tnon:SeriesEWarrantsMember tnon:TwoThousandTwentySixPrivatePlacementOfferingMember 2025-03-25 0001560293 tnon:SeriesEWarrantsMember tnon:TwoThousandTwentySixPrivatePlacementOfferingMember 2025-03-25 2025-03-25 0001560293 tnon:SeriesDWarrantsMember 2026-01-01 2026-09-30 0001560293 tnon:TwoThousandTwentySixPrivatePlacementOfferingMember tnon:SeriesC-TwoCommonStockWarrantsMember 2025-03-11 0001560293 tnon:TwoThousandTwentySixPrivatePlacementOfferingMember tnon:SeriesC-TwoCommonStockWarrantsMember 2025-03-11 2025-03-11 0001560293 tnon:TwoThousandTwentySixPrivatePlacementOfferingMember tnon:SeriesC-OneCommonStockWarrantsMember 2025-03-11 0001560293 tnon:TwoThousandTwentySixPrivatePlacementOfferingMember tnon:SeriesC-OneCommonStockWarrantsMember 2025-03-11 2025-03-11 0001560293 tnon:TwoThousandTwentySixPrivatePlacementOfferingMember 2026-08-31 0001560293 tnon:TwoThousandTwentySixPrivatePlacementOfferingMember tnon:SeriesAWarrantsMember 2026-09-30 0001560293 tnon:TwoThousandTwentySixPrivatePlacementOfferingMember tnon:SeriesAWarrantsMember 2026-08-27 2026-08-27 0001560293 tnon:PreFundedWarrantsMember tnon:TwoThousandTwentySixPrivatePlacementOfferingMember 2026-08-27 0001560293 us-gaap:CommonStockMember tnon:TwoThousandTwentySixPrivatePlacementOfferingMember 2026-08-27 2026-08-27 0001560293 2026-08-11 0001560293 tnon:AttheMarketOfferingProgramMember 2026-08-11 0001560293 tnon:AttheMarketOfferingProgramMember 2026-01-01 2026-09-30 0001560293 us-gaap:CommonStockMember 2026-09-30 0001560293 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001560293 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001560293 2026-08-11 2026-08-11 0001560293 tnon:TwoThousandTwentySixPublicOfferingMember 2026-01-01 2026-09-30 0001560293 tnon:PlacementAgentWarrantsMember 2026-01-01 2026-09-30 0001560293 us-gaap:CommonStockMember tnon:PlacementAgentWarrantsMember 2026-01-01 2026-09-30 0001560293 us-gaap:CommonStockMember tnon:TwoThousandTwentySixPublicOfferingMember 2026-07-01 0001560293 us-gaap:WarrantMember tnon:TwoThousandTwentySixPublicOfferingMember 2026-07-01 0001560293 tnon:PreFundedWarrantsMember tnon:TwoThousandTwentySixPublicOfferingMember 2026-07-01 2026-07-01 0001560293 us-gaap:CommonStockMember us-gaap:WarrantMember tnon:TwoThousandTwentySixPublicOfferingMember 2026-07-01 0001560293 us-gaap:CommonStockMember us-gaap:WarrantMember tnon:TwoThousandTwentySixPublicOfferingMember 2026-07-01 2026-07-01 0001560293 us-gaap:CommonStockMember tnon:TwoThousandTwentySixPublicOfferingMember 2026-07-01 2026-07-01 0001560293 us-gaap:CommonStockMember tnon:PreFundedWarrantsMember tnon:TwoThousandTwentySixPublicOfferingMember 2026-07-01 0001560293 tnon:TwoThousandTwentyFiveSecuritiesPurchaseAgreementsMember 2025-03-25 2025-03-25 0001560293 tnon:TwoThousandTwentyFiveSecuritiesPurchaseAgreementsMember 2025-03-25 0001560293 tnon:PurchaseAgreementMember 2025-03-25 2025-03-25 0001560293 tnon:TwoThousandTwentyFiveSecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember 2025-03-25 0001560293 tnon:TwoThousandTwentyFiveSecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember 2025-03-25 2025-03-25 0001560293 2025-03-11 2025-03-11 0001560293 tnon:TwoThousandTwentyFiveWarrantInducementMember 2025-03-11 2025-03-11 0001560293 tnon:NewWarrantsMember 2025-03-11 0001560293 tnon:TwoThousandTwentyFiveWarrantInducementMember 2025-03-11 0001560293 tnon:AttheMarketOfferingProgramMember 2026-05-04 0001560293 tnon:AttheMarketOfferingProgramMember 2023-05-04 2023-05-04 0001560293 us-gaap:SeriesBPreferredStockMember 2014-02-18 0001560293 us-gaap:SeriesAPreferredStockMember 2014-02-18 0001560293 us-gaap:PreferredStockMember 2014-02-18 0001560293 us-gaap:CommonStockMember 2014-02-18 0001560293 tnon:ConvertiblePromissoryNotesMember 2026-01-01 2026-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember 2026-09-01 2026-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember 2026-08-01 2026-08-31 0001560293 tnon:ConvertiblePromissoryNotesMember 2026-09-30 0001560293 tnon:ConvertiblePromissoryNotesMember 2026-03-11 2026-03-11 0001560293 tnon:ConvertiblePromissoryNotesMember 2026-03-11 0001560293 us-gaap:PrivatePlacementMember tnon:ConvertiblePromissoryNotesMember 2026-03-11 0001560293 us-gaap:CustomerRelationshipsMember 2025-12-31 0001560293 tnon:TrademarkstradeNamesMember 2025-12-31 0001560293 tnon:DevelopedTechnologyMember 2025-12-31 0001560293 us-gaap:CustomerRelationshipsMember 2026-09-30 0001560293 tnon:TrademarkstradeNamesMember 2026-09-30 0001560293 tnon:DevelopedTechnologyMember 2026-09-30 0001560293 us-gaap:CustomerRelationshipsMember 2026-09-30 0001560293 us-gaap:TrademarksAndTradeNamesMember 2026-09-30 0001560293 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2026-09-30 0001560293 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2026-09-30 0001560293 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001560293 us-gaap:FurnitureAndFixturesMember 2026-09-30 0001560293 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001560293 us-gaap:LeaseholdImprovementsMember 2026-09-30 0001560293 us-gaap:EquipmentMember 2025-12-31 0001560293 us-gaap:EquipmentMember 2026-09-30 0001560293 tnon:LabEquipmentMember 2025-12-31 0001560293 tnon:LabEquipmentMember 2026-09-30 0001560293 us-gaap:ConstructionInProgressMember 2025-12-31 0001560293 us-gaap:ConstructionInProgressMember 2026-09-30 0001560293 tnon:InstrumentTraySetsMember 2025-12-31 0001560293 tnon:InstrumentTraySetsMember 2026-09-30 0001560293 us-gaap:ConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001560293 us-gaap:ConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001560293 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001560293 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001560293 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001560293 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001560293 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001560293 2026-05-21 2026-05-21 0001560293 2026-02-25 2026-02-25 0001560293 2026-02-25 0001560293 2026-01-09 2026-02-24 0001560293 tnon:TheNasdaqStockMarketLLCMember 2026-02-25 2026-02-25 0001560293 2025-09-30 0001560293 2024-12-31 0001560293 us-gaap:RetainedEarningsMember 2025-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001560293 us-gaap:CommonStockMember 2025-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2025-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2025-09-30 0001560293 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001560293 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001560293 us-gaap:RetainedEarningsMember 2024-12-31 0001560293 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001560293 us-gaap:CommonStockMember 2024-12-31 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2024-12-31 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2024-12-31 0001560293 us-gaap:RetainedEarningsMember 2026-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2026-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2026-09-30 0001560293 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001560293 us-gaap:RetainedEarningsMember 2025-12-31 0001560293 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001560293 us-gaap:CommonStockMember 2025-12-31 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2025-12-31 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2025-12-31 0001560293 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001560293 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2025-07-01 2025-09-30 0001560293 2025-06-30 0001560293 us-gaap:RetainedEarningsMember 2025-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001560293 us-gaap:CommonStockMember 2025-06-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2025-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2025-06-30 0001560293 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001560293 2026-06-30 0001560293 us-gaap:RetainedEarningsMember 2026-06-30 0001560293 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001560293 us-gaap:CommonStockMember 2026-06-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2026-06-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2026-06-30 0001560293 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001560293 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001560293 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001560293 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001560293 2026-11-16 0001560293 tnon:WarrantsMember 2026-01-01 2026-09-30 0001560293 tnon:CommonStockParValue0001PerShareMember 2026-01-01 2026-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2026-07-01 2026-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2026-07-01 2026-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2025-07-01 2025-09-30 0001560293 tnon:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001560293 tnon:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001560293 us-gaap:WarrantMember 2026-09-30 0001560293 tnon:SeriesAWarrantLiabilityMember 2025-12-31 0001560293 us-gaap:DerivativeMember 2025-12-31 0001560293 us-gaap:DerivativeMember 2026-09-30 0001560293 us-gaap:WarrantMember 2025-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure tnon:Segments

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM  _________ to __________

 

COMMISSION FILE NUMBER 001-41364

 

TENON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   45-5574718

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

104 Cooper Court

Los Gatos, CA  95032

  (408) 649-5760
(Address of principal executive offices) (Zip Code)   (Registrant’s telephone number, including area code)

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TNON   The Nasdaq Stock Market LLC
Warrants   TNONW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒    No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒    No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes  ☐   No  ☒

 

As of November 16, 2026, the registrant had a total of 2,682,728 shares of its common stock, par value $0.001 per share, issued and outstanding.

 

 

 

 

 

 

INDEX

    Page
PART I. FINANCIAL INFORMATION 1
Item 1. Condensed Financial Statements (unaudited) 1
  Condensed Balance Sheets 1
  Condensed Statements of Operations and Comprehensive Loss 2
  Condensed Statements of Stockholders’ (Deficit) Equity 3
  Condensed Statements of Cash Flows 5
  Notes to Condensed Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
Item 3. Quantitative and Qualitative Disclosures About Market Risk 26
Item 4. Controls and Procedures 26
PART II. OTHER INFORMATION 27
Item 1. Legal Proceedings 27
Item 1A. Risk Factors 27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27
Item 3. Defaults Upon Senior Securities 27
Item 4. Mine Safety Disclosures 27
Item 5. Other Information 27
Item 6. Exhibits 28
SIGNATURES 32

 

i

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends impacting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

 

Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “intend,” “seek,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential,” “might,” “forecast,” “continue,” or the negative of those terms, and similar expressions and comparable terminology intended to reference future periods. Forward-looking statements include, but are not limited to, statements about:

 

●Our ability to effectively operate our business;

 

●Our ability to manage our research, development, expansion, growth and operating expenses;

 

●Our ability to evaluate and measure our business, prospects and performance metrics;

 

●Our ability and our distributors’ ability to compete, directly and indirectly, and succeed in the highly competitive medical devices industry;

 

●Our ability to respond and adapt to changes in technology and customer behavior;

 

●Our ability to raise the needed capital to fund our operations;

 

●Our ability to protect our intellectual property and to develop, maintain and enhance a strong brand; and

 

●Other factors (including the risks contained in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 27, 2026) relating to our industry, our operations, and results of operations. 

 

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

 

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Accordingly, the forward-looking statements in this Quarterly Report on Form 10-Q should not be regarded as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved, and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements.

 

ii

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. Condensed Financial Statements (Unaudited)

 

Tenon Medical, Inc.

Condensed Balance Sheets (Unaudited)

(In thousands, except share data)

 

    September 30,     December 31,  
    2026     2025  
ASSETS            
Current assets:            
Cash and cash equivalents   $ 8,271     $ 3,756  
Accounts receivable, net     1,701       1,698  
Inventory     882       1,054  
Prepaid expenses and other current assets     367       260  
Total current assets     11,221       6,768  
Property and equipment, net (Note 3)     717       918  
Deposits     51       51  
Operating lease right-of-use asset (Note 6)     1,362       131  
Intangible assets, net (Note 4)     441       485  
Goodwill     2,407       2,407  
TOTAL ASSETS   $ 16,199     $ 10,760  
                 
Liabilities and Stockholders’ EQUITY                
Current liabilities:                
Accounts payable   $ 657     $ 845  
Accrued expenses (Note 5)     2,151       1,637  
Current portion of accrued commissions     780       590  
Current portion of operating lease liability (Note 6)     222       141  
Current portion of contingent consideration (Note 10)     23       —  
Total current liabilities     3,833       3,213  
Accrued commissions, net of current portion     1,086       1,514  
Operating lease liability, net of current portion (Note 6)     1,071       —  
Contingent consideration, net of current portion (Note 10)     991       993  
Total liabilities     6,981       5,720  
                 
Commitments and contingencies (Note 10)                
Stockholders’ equity:                
Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at September 30, 2026 and December 31, 2025; 204,159 shares issued and outstanding at September 30, 2026 and December 31, 2025     2,622       2,622  
Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at September 30, 2026 and December 31, 2025; 86,454 shares issued and outstanding at September 30, 2026 and December 31, 2025     452       452  
Common stock, $0.001 par value; 130,000,000 shares authorized at September 30, 2026 and December 31, 2025; 2,682,721 and 310,036 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively     3       —  
Additional paid-in capital     101,608       83,268  
Accumulated deficit     (95,467 )     (81,302 )
Total stockholders’ equity     9,218       5,040  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 16,199     $ 10,760  

 

The accompanying notes are an integral part of these condensed financial statements.

 

1

 

Tenon Medical, Inc.

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

(In thousands, except per share data)

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Revenue   $ 1,432     $ 1,173     $ 4,090     $ 2,463  
Cost of sales     482       400       1,381       1,122  
Gross Profit     950       773       2,709       1,341  
                                 
Operating Expenses                                
Research and development     804       428       2,234       1,622  
Sales and marketing     1,714       1,538       5,441       4,304  
General and administrative     1,517       2,199       4,753       5,341  
Total Operating Expenses     4,035       4,165       12,428       11,267  
                                 
Loss from Operations     (3,085 )     (3,392 )     (9,719 )     (9,926 )
                                 
Other Income (Expense)                                
Gain on investments     43       53       92       202  
Interest expense     (719 )     —       (1,747 )     —  
Other expense, net     (2,878 )     —       (2,791 )     —  
Total Other (Expense) Income, net     (3,554 )     53       (4,446 )     202  
Net Loss and Comprehensive Loss   $ (6,639 )   $ (3,339 )   $ (14,165 )   $ (9,724 )
Net Loss Per Share of Common Stock                                
Basic and diluted   $ (5.39 )   $ (14.17 )   $ (22.48 )   $ (51.72 )
                                 
Weighted-Average Shares of Common Stock Outstanding                                
Basic and diluted     1,231       236       630       188  

 

The accompanying notes are an integral part of these condensed financial statements.

 

2

 

Tenon Medical, Inc.

Condensed Statements of Stockholders’ (Deficit) Equity (Unaudited)

(In thousands, except share data)

 

Three months ended September 30, 2026 and 2025:

 

    Series A Convertible Preferred Stock     Series B Convertible Preferred Stock     Common Stock     Additional
Paid-In
    Accumulated        
    Shares     Amount     Shares     Amount     Shares     Amount     Capital     Deficit     Total  
Balance at June 30, 2026     204,159     $ 2,622       86,454     $ 452       330,670     $ —     $ 84,011     $ (88,828 )   $ (1,743 )
Stock-based compensation expense     —       —       —       —       —       —       120       —       120  
Release of restricted stock units     —       —       —       —       12,686       —       —       —       —  
Issuance of common stock, prefunded warrants and warrants in a public offering, net of derivative liability and issuance costs     —       —       —       —       315,789       —       944       —       944  
Issuance of prefunded warrants and warrants in private offering, net of derivative liability and issuance costs     —       —       —       —       597,610       1       110       —       111  
Issuance of common stock and warrants under inducement agreement     —       —       —       —       572,179       1       5,675       —       5,676  
Issuance of common stock, net of issuance costs     —       —       —       —       345,187       —       2,693       —       2,693  
Issuance of common stock upon exercise of warrants     —       —       —       —       506,639       1       2,711       —       2,712  
Reclassification of warrant liability to equity     —       —       —       —       —       —       5,344       —       5,344  
Vesting of restricted shares     —       —       —       —       1,879       —       —       —       —  
Shares issued for reverse stock split     —       —       —       —       82       —       —       —       —  
Net loss     —       —       —       —       —       —       —       (6,639 )     (6,639 )
Balance at September 30, 2026     204,159     $ 2,622       86,454     $ 452       2,682,721     $ 3     $ 101,608     $ (95,467 )   $ 9,218  
                                                                         
Balance at June 30, 2025     256,968     $ 3,300       86,454     $ 452       216,920     $ —     $ 78,092     $ (75,131 )   $ 6,713  
Stock-based compensation expense     —       —       —       —       —       —       58       —       58  
Shares issued for acquisition of assets of SiVantage, Inc.     —       —       —       —       20,295       —       1,366       —       1,366  
Issuance of common stock upon conversion of Series A convertible preferred stock     (52,809 )     (678 )     —       —       8,572       —       678       —       —  
Release of restricted stock units     —       —       —       —       85       —       —       —       —  
Net loss     —       —       —       —       —       —       —       (3,339 )     (3,339 )
Balance at September 30, 2025     204,159     $ 2,622       86,454     $ 452       245,872     $ —     $ 80,194     $ (78,470 )   $ 4,798  

 

3

 

Nine months ended September 30, 2026 and 2025:

 

    Series A Convertible Preferred Stock     Series B Convertible Preferred Stock     Common Stock     Additional
Paid-In
    Accumulated        
    Shares     Amount     Shares     Amount     Shares     Amount     Capital     Deficit     Total  
Balance at December 31, 2025     204,159     $ 2,622       86,454     $ 452       310,036     $ —     $ 83,268     $ (81,302 )   $ 5,040  
Stock-based compensation expense     —       —       —       —       —       —       863       —       863  
Release of restricted stock units     —       —       —       —       25,428       —       —       —       —  
Issuance of common stock to SiVantage upon completion of milestone     —       —       —       —       7,892       —       —       —       —  
Issuance of common stock, prefunded warrants and warrants in a public offering, net of derivative liability and issuance costs     —       —       —       —       315,789       —       944       —       944  
Issuance of prefunded warrants and warrants in private offering, net of derivative liability and issuance costs     —       —       —       —       597,610       1       110       —       111  
Issuance of common stock and warrants under inducement agreement     —       —       —       —       572,179       1       5,675       —       5,676  
Issuance of common stock, net of issuance costs     —       —       —       —       345,187       —       2,693       —       2,693  
Issuance of common stock upon exercise of warrants     —       —       —       —       506,639       1       2,711       —       2,712  
Reclassification of warrant liability to equity     —       —       —       —       —       —       5,344       —       5,344  
Vesting of restricted shares     —       —       —       —       1,879       —       —       —       —  
Shares issued for reverse stock split     —       —       —       —       82       —       —       —       —  
                                                                         
Net loss     —       —       —       —       —       —       —       (14,165 )     (14,165 )
Balance at September 30, 2026     204,159     $ 2,622       86,454     $ 452       2,682,721     $ 3     $ 101,608     $ (95,467 )   $ 9,218  
                                                                         
Balance at December 31, 2024     256,968     $ 3,300       86,454     $ 452       89,680     $ —     $ 70,965     $ (68,746 )   $ 5,971  
Stock-based compensation expense     —       —       —       —       —       —       1,347       —       1,347  
Issuance of common stock, pre-funded warrants and warrants under inducement agreement, net of issuance costs     —       —       —       —       69,877       —       2,735       —       2,735  
Issuance of common stock, pre-funded warrants, and warrants, net of issuance costs     —       —       —       —       57,286       —       3,524       —       3,524  
Shares issued for acquisition of assets of SiVantage, Inc.                                     20,295               1,366               1,366  
Issuance of common stock upon conversion of Series A convertible preferred stock     (52,809 )     (678 )                     8,572               678                  
Release of restricted stock units     —       —       —       —       162       —       —       —       —  
Deferred financing costs     —       —       —       —       —       —       (421 )     —       (421 )
Net loss     —       —       —       —       —       —       —       (9,724 )     (9,724 )
Balance at September 30, 2025     204,159     $ 2,622       86,454     $ 452       245,872     $ —     $ 80,194     $ (78,470 )   $ 4,798  

 

The accompanying notes are an integral part of these condensed financial statements.

 

4

 

Tenon Medical, Inc.

Condensed Statements of Cash Flows (Unaudited)

(In thousands)

 

    Nine Months Ended
September 30,
 
    2026     2025  
Cash Flows from Operating Activities            
Net loss   $ (14,165 )   $ (9,724 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Stock-based compensation expense     863       1,347  
Depreciation and amortization     224       167  
Amortization of debt discount     1,748       —  
Change in fair value of derivative liabilities     (1,254 )     —  
Issuance of warrants as inducement consideration     3,113       —  
Offering costs allocated to derivative liabilities     857       —  
Loss on extinguishment of debt     74       —  
Amortization of operating right-of-use asset     202       199  
Provision for credit losses on accounts receivable     3       —  
Increase (decrease) in cash resulting from changes in:                
Accounts receivable     (6 )     (448 )
Inventory     429       (554 )
Prepaid expenses and other assets     (132 )     (203 )
Accounts payable     (188 )     266  
Accrued expenses     297       641  
Operating lease liability     (171 )     (212 )
Net cash used in operating activities     (8,106 )     (8,521 )
                 
Cash Flows from Investing Activities                
Purchase of assets from SiVantage, Inc.     —       (750 )
Purchases of property and equipment     (236 )     (81 )
Cash used in investing activities     (236 )     (831 )
                 
Cash Flows from Financing Activities                
Gross proceeds from issuance of convertible notes     4,300       —  
Repayment of convertible notes payable     (5,126 )     —  
Gross proceeds from issuance of common stock, pre-funded warrants and warrants     7,200       4,010  
Gross proceeds from issuance of common stock, pre-funded warrants and warrants under inducement agreement     2,872       3,057  
Gross proceeds from issuance of common stock     2,809       —  
Gross proceeds from issuance of common stock upon exercise of warrants     2,712       —  
Offering costs     (1,910 )     (808 )
Net cash provided by financing activities     12,857       6,259  
Net Increase (Decrease) in Cash and Cash Equivalents     4,515       (3,093 )
Cash and Cash Equivalents at Beginning of Period     3,756       6,535  
Cash and Cash Equivalents at End of Period   $ 8,271     $ 3,442  
                 
Supplemental Disclosures of Cash Flow Information                
Non-cash investing and financing activities:                
Remeasurement of right-of-use asset and lease liability   $ 1,323     $ —  
Initial fair value of derivative liability recorded as a debt discount   $ 563     $ —  
Reclassification of warrant derivative liability to equity   $ 5,344     $ —  
Warrant modification costs   $ —     $ 1,402  
Reclassification of deferred offering costs to additional paid-in capital   $ —     $ 421  
Common stock issued upon conversion of Series A preferred stock   $ —     $ 678  
Common stock issued for purchase of assets from SiVantage, Inc.   $ —     $ 1,366  
Contingent consideration for purchase of assets from SiVantage, Inc.   $ —     $ 1,011  

 

The accompanying notes are an integral part of these condensed financial statements.

 

5

 

Tenon Medical Inc.

Notes to Condensed Financial Statements (unaudited)
(in thousands, except share and per-share data)

 

1. Organization and Business

 

Nature of operations

 

Tenon Medical, Inc. (the “Company”) was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. The Company currently offers two systems to treat a diseased sacroiliac joint (“SI Joint”). The Company has developed The Catamaran® SI Joint Fusion System (“The Catamaran System”) that offers a novel, less invasive approach to the SI Joint using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of The Catamaran System in October 2022, the Company has been focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct.

 

In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+ SI Joint Fusion System (“The SImmetry+ System”) that treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles-including joint decortication, bone graft placement, and rigid fixation-with the goal of achieving a true biological fusion across the SI Joint.

 

2.  Summary of Significant Accounting Policies

 

Basis of presentation

 

The accompanying unaudited condensed financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). As permitted under these rules and regulations, the Company has condensed or omitted certain financial information and footnote disclosures normally included in its annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed balance sheet as of December 31, 2025 has been derived from the Company’s audited financial statements, which are included in its Annual Report on Form 10-K filed with the SEC on March 27, 2026 (the “Annual Report”).

 

These condensed financial statements have been prepared on the same basis as the Company’s annual financial statements and, in management’s opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair presentation of its financial information. The interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.

 

These unaudited condensed financial statements and accompanying notes should be read in conjunction with the Company’s audited financial statements as of and for the years ended December 31, 2025 and 2024 included in its Annual Report.

 

The Company’s significant accounting policies are disclosed in the Annual Report. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2026 with the exception of the policy for accounting for derivatives which is included below.

 

Going concern uncertainty and liquidity requirements

 

The accompanying condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued.

 

Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System and The SImmetry+ System. Based on the Company’s expected level of revenues and expenditures, the Company believes that its existing cash and cash equivalents as of September 30, 2026 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

6

 

Reverse Stock Split

 

On August 10, 2026, the Company effected a 1-for-35 reverse stock split (the “Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The Reverse Stock Split combined every 35 shares of our common stock issued and outstanding immediately prior to effecting the Reverse Stock Split into one share of common stock. No fractional shares were issued in connection with the Reverse Stock Split. Any potential fractional shares were rounded up.

 

All historical share and per share amounts reflected throughout this document have been adjusted to reflect the Reverse Stock Split. The authorized number of shares and the par value per share of the Company’s common stock, Series A preferred stock and Series B preferred stock were not affected by the Reverse Stock Split.

 

Notices from Nasdaq

 

On February 25, 2026, the Company received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the 30 consecutive business day period between January 9, 2026 and February 24, 2026, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until August 24, 2026 (the “Compliance Period”), to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during the Compliance Period.

 

On August 24, 2026, due to the Reverse Stock Split, the Company received written notification from Nasdaq confirming that the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and this matter is now closed.

 

On May 21, 2026, the Company received a written notice from Nasdaq, notifying the Company that it was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million. In addition, the Company did not meet the alternative compliance standards relating to the market value of listed securities or net income from continuing operations.

 

On July 10, 2026, the Company filed a Current Report on Form 8-K disclosing that it believed that it had satisfied the minimum stockholders’ equity requirement. On July 17, 2026, the Company received a notice from Nasdaq stating that, based on the July 10, 2026 Form 8-K, it had regained compliance with the stockholders’ equity rule.

 

Use of estimates

 

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, collectability of accounts receivable, impairment of long-lived assets, accrued liabilities, accrued commissions, contingent consideration, derivative liability valuation, incremental borrowing rate, obsolescence of inventory and stock-based compensation.

 

Derivative Liabilities

 

The Company accounts for certain features in its free-standing financial instruments and embedded in its financial instruments as derivative liabilities in accordance with ASC 815. The Company evaluates all financial instruments, including convertible debt and equity-linked instruments, to determine whether such instruments or embedded features meet the definition of a derivative and require bifurcation under ASC 815.

 

Derivative liabilities are initially recorded at fair value at the date of issuance, with a corresponding adjustment to the carrying amount of the host instrument, if applicable. For derivative liabilities related to debt, the initial fair value of the derivative is recognized as a debt discount and amortized to interest expense over the term of the related instrument using the effective interest method.

 

Subsequent to initial recognition, derivative liabilities are remeasured at fair value at each reporting date, and immediately before settlement, in accordance with ASC 820. Changes in the fair value of derivative liabilities are recognized in the condensed statements of operations within other income (expense).

 

7

 

The fair value of derivative liabilities is determined using valuation techniques that include significant unobservable inputs, including expected stock price volatility, expected term, and risk-free interest rates. Accordingly, derivative liabilities are generally classified within Level 3 of the fair value hierarchy. The Company utilizes valuation models, including Monte Carlo simulation models, when appropriate, to estimate the fair value of derivative liabilities. These models incorporate assumptions regarding the probability and timing of conversion or settlement, as well as other relevant contractual features.

 

Derivative liabilities are classified as current or non-current based on the expected timing of settlement in accordance with applicable balance sheet classification guidance. In most cases, derivative liabilities are classified as current due to the potential for settlement within twelve months. Upon settlement or conversion of the underlying instrument, the related derivative liability is derecognized, and any remaining carrying value is reclassified to equity or recognized in earnings, as appropriate.

 

Other income (expense), net

 

Other income (expense), net consisted of the following:

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Issuance of warrants as inducement consideration (Note 8)   $ (3,113 )   $ —     $ (3,113 )   $ —  
Change in fair value of derivative liabilities (Note 9)     1,166       —       1,254       —  
Offering costs allocated to derivative liabilities (Note 9)     (857 )     —       (857 )     —  
Loss on extinguishment of debt (Note 7)     (74 )     —       (74 )     —  
Other income (expense), net   $ (2,878 )   $ —     $ (2,791 )   $ —  

 

Amounts may not sum due to rounding.

 

Net loss per share

 

Basic net loss per share is based upon the weighted average number of common shares outstanding. Qualifying pre-funded warrants are counted as shares outstanding for the calculation of basic net loss per share on the date of the issuance of the pre-funded warrants. Diluted net loss per share is based on the assumption that all potential common stock equivalents (restricted stock units, stock options, warrants, convertible preferred stock and convertible notes) are converted or exercised pursuant to the if-converted method or the treasury stock method. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. The Company’s weighted average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive.

 

The Company had the following potential common shares excluded because their effect was anti-dilutive as of September 30, 2026 and 2025:

 

    September 30,
2026
    September 30,
2025
 
Outstanding restricted stock units     4,081       2,614  
Outstanding stock options     284       506  
Outstanding warrants     1,392,580       170,172  
Common shares convertible from preferred stock     151,837       39,267  
Total     1,548,782       212,559  

 

Adoption of New Accounting Pronouncement

 

In July 2025, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient to measure credit losses on current accounts receivable and contract assets. The practical expedient allows companies to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. For public companies, this guidance is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted this guidance as of January 1, 2026. The adoption of this guidance had no material impact on the Company’s condensed financial statements.

 

Recent Accounting Pronouncements Not Yet Adopted

 

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires additional disclosure of specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. We are currently evaluating the impact of adopting this new accounting guidance.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments clarify the applicability of interim reporting guidance, consolidate interim disclosure requirements within Topic 270 and establish a disclosure principle requiring disclosure of events occurring since the end of the last annual reporting period that have a material impact on the entity. The guidance is effective for the Company for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The amendments may be applied prospectively or retrospectively to any or all prior periods presented. The Company is currently evaluating the impact of this guidance on its interim financial statement disclosures.

 

8

 

3. Property and Equipment, net

 

Property and equipment, net, consisted of the following: 

 

   

September 30,

2026

   

December 31,

2025

 
Instrument tray sets   $ 859     $ 829  
Construction in progress     779       836  
Lab equipment     79       79  
IT equipment     56       56  
Leasehold improvements     15       15  
Office furniture     15       9  
Property and equipment, gross     1,803       1,824  
Less: accumulated depreciation     (1,086 )     (906 )
Property and equipment, net   $ 717     $ 918  

 

Construction in progress is made up of reusable components that will become reusable instrument tray sets. Depreciation expense was approximately $62 and $68 for the three months ended September 30, 2026 and 2025, respectively, and $180 and $158 for the nine months ended September 30, 2026 and 2025, respectively.

 

4. Intangible Assets, net

 

The Company’s intangible assets, net relate to developed technology, trademarks/trade names and customer relationships acquired in connection with the acquisition of substantially all of the assets of SiVantage, Inc. (“SI”) and SIMPL Medical, LLC (the “SI Acquisition”) as described in the Company’s Annual Report. Intangible assets were valued based on their estimated fair value on the date of acquisition and are being amortized on a straight-line basis over estimated useful lives of 7-8 years for developed technology, 10 years for trademarks/trade names and 8 years for customer relationships.

 

Intangible assets as of September 30, 2026 consist of the following:

 

    Gross Value     Accumulated
Amortization
    Net Value  
Developed technology   $ 103     $ (15 )   $ 88  
Trademarks/trade names     196       (23 )     173  
Customer relationships     210       (30 )     180  
Total   $ 509     $ (68 )   $ 441  

 

Intangible assets as of December 31, 2025 consist of the following:

 

    Gross Value     Accumulated
Amortization
    Net Value  
Developed technology   $ 103     $ (5 )   $ 98  
Trademarks/trade names     196       (8 )     188  
Customer relationships     210       (11 )     199  
Total   $ 509     $ (24 )   $ 485  

 

Amortization expense for three months ended September 30, 2026 and 2025 was $14 and $9, respectively and $44 and $9 for the nine months ended September 30, 2026 and 2025, respectively.

 

As of September 30, 2026, future amortization of amortizable intangible assets is as follows:

 

2026 (remaining 3 months)   $ 15  
2027     59  
2028     59  
2029     59  
2030     59  
Thereafter     190  
    $ 441  

 

9

 

5. Accrued Expenses

 

Accrued expenses consisted of the following: 

 

   

September 30,

2026

   

December 31,

2025

 
Accrued compensation   $ 1,101     $ 710  
Accrued professional services fees     513       484  
Other accrued expenses     537       443  
Total accrued expenses   $ 2,151     $ 1,637  

 

6. Leases

 

In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California, which was to expire in June 2026. In February 2026, the Company entered into a lease extension for the same facility. This non-cancellable operating lease expires in May 2031. In April 2026, the Company entered into a prepaid lease agreement for a sales facility in Tampa, Florida, which expires in April 2028. Operating lease expense for the facility leases was $96 and $73 for the three months ended September 30, 2026 and 2025, respectively and $267 and $219 for the nine months ended September 30, 2026 and 2025, respectively.

 

Supplemental balance sheet information related to leases was as follows:

 

    September 30,     December 31,  
    2026     2025  
Operating lease right-of-use assets   $ 1,362     $ 131  
                 
Operating lease liability, current   $ 222     $ 141  
Operating lease liability, noncurrent     1,071       —  
Total operating lease liabilities   $ 1,293     $ 141  

 

Future maturities of operating lease liabilities as of September 30, 2026 were as follows:

 

2026 (remaining 3 months)   $ 78  
2027     320  
2028     329  
2029     338  
2030     348  
Thereafter     147  
Total lease payments     1,560  
Less: imputed interest     (267 )
Present value of operating lease liabilities   $ 1,293  

 

Other information:

 

Cash paid for operating leases for the nine months ended September 30, 2026   $ 346  
Cash paid for operating leases for the nine months ended September 30, 2025   $ 232  
Remaining weighted-average lease term - operating leases (in years)     4.67  
Weighted-average discount rate - operating leases     8.0 %

 

7. Debt

 

Convertible Promissory Notes

 

On March 11, 2026, the Company entered into securities purchase agreements with certain accredited investors, pursuant to which the Company agreed to issue and sell in a private placement 20% original issue discount senior convertible promissory notes (the “Convertible Promissory Notes”) with aggregate gross proceeds of $4,300 and a principal amount of $5,160 and with placement agent expenses of $433.

 

The Convertible Promissory Notes have a maturity date of September 11, 2026, which, at the option of the Company, can be extended until December 11, 2026.

 

Following the six month anniversary of the issuance date, the Convertible Promissory Notes will be convertible at any time at the option of the holder into shares of the Company’s common stock at a conversion price per share equal to the greater of 80% of the VWAP for the 3 trading days immediately prior to the date of conversion and $5.4845, subject to adjustment for stock splits and pro rata distributions as provided in the Convertible Promissory Notes.

 

If the maturity date of the Convertible Promissory Notes is extended, the outstanding principal amount will be increased by 5%. Any prepayment of the Convertible Promissory Notes will be prepaid at 102.5% of the principal prepayment. In addition, the Company is required to prepay the Convertible Promissory Notes from 15% of the net proceeds it may receive from future securities financing transactions less certain amount attributable to the original issue discount.

 

10

 

The Company repaid the Convertible Promissory Notes in full by making prepayments totaling $5,126 in August and September of 2026, each of which, per the terms of the Convertible Promissory Notes, reduced the principal. The Company recorded a loss on the early extinguishment of the debt of $74.

 

For the three and nine months ended September 30, 2026, the Company recorded interest expense, which included the amortization of the discount, the initial value of the derivative liability and transaction costs of $719 and $1,747, respectively, related to the Convertible Promissory Notes.

 

8. Stockholders’ Equity

 

The Company’s current Amended and Restated Certificate of Incorporation dated February 18, 2014 authorizes the issuance of 130,000,000 shares of common stock and 20,000,000 shares of preferred stock, both with a par value of $0.001 per share. Of the preferred stock, 4,500,000 shares are designated Series A Preferred Stock and 491,222 shares are designated Series B Preferred Stock.

 

2023 At-the-Market Offering Program

 

On May 4, 2023, the Company entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Maxim Group LLC (the “2023 Sales Agent”) to establish an at-the-market offering program, under which the Company may sell from time to time, at its option, shares of its common stock having an aggregate gross sales price of $5.5 million. The Company is required to pay the 2023 Sales Agent a commission of 3% of the gross proceeds from the sale of shares and has also agreed to provide the 2023 Sales Agent with customary indemnification rights. During the three and nine months ended September 30, 2026 and 2025, no shares of the Company’s common stock were sold under the program. Per the terms of the Equity Distribution Agreement, no shares are available to be issued under the program as of September 30, 2026.

 

2025 Warrant Inducement

 

On March 11, 2025, the Company entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with the holder of the Series A New Warrants and Series B New Warrants (the “Existing Warrants”), pursuant to which, the holder agreed to exercise the Existing Warrants at a reduced exercise price of $43.75 per share in consideration for the Company’s agreement to issue (i) new unregistered five-year warrants (the “Series C-1 Warrants”) to purchase up to an aggregate of 69,878 shares of common stock at an exercise price of $43.75 per share and (ii) new unregistered three-year warrants (the “Series C-2 Warrants,” and together with the Series C-1 Warrants, the “New Warrants”) to purchase up to an aggregate of 34,939 shares of common stock at an exercise price of $43.75 per share (the “2025 Warrant Inducement”). The New Warrants were not exercisable without approval by the Company’s stockholders, which was obtained on September 18, 2025 (the “Approval Date”). The Series C-1 Warrants were to expire five years from the Approval Date, and the Series C-2 Warrants were to expire three years from the Approval Date. Pursuant to the 2025 Warrant Inducement, the Company received proceeds, net of financial advisor fees and other transaction expenses, of approximately $2,735. The incremental value of the consideration to the holders of the Existing Warrants was $5,113.

 

The Company filed a registration statement on Form S-1 on April 4, 2025 providing for the resale of the shares of common stock issuable upon the exercise of the New Warrants. All of the New Warrants were cancelled in connection with the 2026 Private Placement.

 

2025 Securities Purchase Agreements

 

On March 25, 2025, the Company entered into a securities purchase agreement for the issuance of 20,958 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering at a purchase price of $70.00 per share. In a concurrent private placement, the Company also agreed to issue to the same investor warrants to purchase up to 20,958 shares of its common stock at an exercise price of $70.00 per share, which will be exercisable immediately, and will expire five years following the date of issuance. Pursuant to the agreements, the Company received proceeds, net of financial advisor fees and other transaction expenses, of $1,234.

 

Also on March 25, 2025, the Company entered into a securities purchase agreement for the issuance of 36,329 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering at a purchase price of $70.00 per share. In a concurrent private placement, the Company also agreed to issue to the same investor warrants to purchase up to 36,329 shares of its common stock at an exercise price of $70.00 per share, which will be exercisable immediately, and will expire five years following the date of issuance. Pursuant to the agreements, the Company received proceeds, net of financial advisor fees and other transaction expenses, of approximately $2,290.

 

2026 Public Offering

 

On July 1, 2026, the Company consummated a best efforts public offering (the “2026 Public Offering”) of an aggregate of (i) 157,895 shares of common stock and pre-funded warrants to purchase up to 157,895 shares of common stock and (ii) common stock purchase warrants (the “July 2026 Warrants”) to purchase up to 378,948 shares of common stock. Each share of common stock issued (or pre-funded warrant in lieu thereof) and accompanying July 2026 Warrants were sold at a combined public offering price of $13.30 per share (inclusive of the pre-funded warrant exercise price of $0.035). All of the pre-funded warrants were exercised in July 2026. Per the terms of the 2026 Public Offering, the number of shares issuable under the July 2026 Warrants increased to 473,685 on August 10, 2026, due to the Reverse Stock Split. Each July 2026 Warrant is immediately exercisable for one share of common stock at an exercise price of $13.30 per share and will expire on the fifth anniversary of the initial exercise date.

 

11

 

In connection with the 2026 Public Offering, the Company paid the placement agent fees and issued the warrants (the “Placement Agent Warrants”) to purchase 9,474 shares of common stock at an exercise price of $15.96 per share. The Placement Agent Warrants will expire on the fifth anniversary of the initial exercise date. The Company received proceeds, net of offering costs, of approximately $3,635 from the 2026 Public Offering.

 

2026 At-the-Market Offering Program

 

On August 11, 2026, the Company entered into a common stock sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “2026 Sales Agent”) to establish an at-the-market offering program (the “2026 ATM”), under which the Company may sell from time to time, at its option, shares of its common stock having an aggregate gross sales price of up to $4,397. The Company is required to pay the 2026 Sales Agent a commission of 3% of the aggregate gross proceeds from each sale of shares under the 2026 ATM and has also agreed to provide the 2026 Sales Agent with customary indemnification rights. During the three and nine months ended September 30, 2026, 345,187 shares of the Company’s common stock were sold under the Sales Agreement at an average price of $8.14 per share for net proceeds of approximately $2,693 and paid the 2026 Sales Agent compensation with respect to such sales of $84. Per the terms of the Sales Agreement, $1,588 worth of shares are available to be issued under the program as of September 30, 2026.

 

On October 16, 2026, the Company filed a prospectus supplement which increased the amount of shares that are eligible to be sold under the 2026 ATM to shares of common stock having an aggregate offering price of up to $7,176, which does not include the $2,809 of shares previously sold under the Sales Agreement (see Note 12).

 

2026 Private Placement Offering

 

On August 27, 2026, the Company entered into a securities purchase agreement with an institutional investor for the issuance and sale in a private placement (the “2026 Private Placement”) of pre-funded warrants to purchase up to an aggregate of 597,610 shares of common stock at a purchase price of $5.019 per pre-funded warrant, and warrants to purchase up to an aggregate of 1,058,517 shares of common stock (the “Series A Warrants”). The 2026 Private Placement closed on August 31, 2026. The pre-funded warrants were all exercised in September 2026. Each Series A Warrant has an exercise price of $5.02 per share, is immediately exercisable and will expire five years from issuance. WallachBeth Capital LLC acted as exclusive placement agent and received a cash fee of 7% of the aggregate gross proceeds, plus reimbursement of certain expenses and legal fees. In connection with the 2026 Private Placement, the Company entered into a registration rights agreement with the investor, dated August 31, 2026, providing for the registration of the resale of the shares underlying the pre-funded warrants and Series A Warrants.

 

As a part of the 2026 Private Placement, Series C-1 Common Stock Warrants for 69,878 shares at $43.75 per share issued on March 11, 2025, Series C-2 Common Stock Warrants for 34,939 shares at $43.75 per share issued on March 11, 2025, Series D Common Stock Warrants for 20,958 shares at $70.00 per share issued on March 25, 2025, and Series E Common Stock Warrants for 36,329 shares at $70.00 per share issued on March 25, 2025, all of which were owned by the investor, were cancelled. The Company received proceeds, net of offering costs, of approximately $2,599 from the 2026 Private Placement.

 

2026 Inducement Agreement

 

On September 11, 2026, the Company entered into an inducement offer letter agreement (the “Inducement Agreement”) with the holder of the remaining outstanding Series A Warrants exercisable for up to 572,179 shares of common stock. The holder agreed to exercise the remaining Series A Warrants for cash at the original exercise price of $5.02 per share in consideration for the Company’s agreement to issue new unregistered five-year Series B Warrants to purchase up to 858,269 shares of common stock (equal to 150% of the shares issued upon exercise of the Series A Warrants) at an exercise price of $5.02 per share. The Series B Warrants will expire five years from the date of issuance. WallachBeth Capital LLC acted as financial advisor and received a cash fee of 7% of the aggregate gross proceeds and reimbursement of legal expenses of up to $65. The Company received proceeds, net of offering costs, of approximately $2,562 from the Inducement Agreement.

 

Equity Awards

 

In 2012, the Board of Directors of the Company (the “Board”) approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the “2012 Plan”), which provided for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which was effective on April 25, 2022. The 2022 Plan provided for the issuance of common stock options, stock appreciation rights, restricted stock, restricted stock units, and performance awards. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such that no new equity awards will be issued by the 2012 Plan.

 

12

 

A summary of the Company’s stock option and restricted stock unit activity under its plans is as follows:

 

    Number of
Shares Subject
to Outstanding
Stock Options
    Weighted
Average
Exercise
Price per
Share
    Number of
Outstanding
Restricted
Stock
Units
    Weighted
Average Grant
Date Fair
Value per
Unit
 
Outstanding at December 31, 2025     506     $ 459.20       26,212     $ 44.10  
Granted     —       —       21,257     $ 26.84  
Released     —       —       (25,428 )   $ 41.08  
Cancelled/Forfeited     (222 )   $ 412.85       (17,960 )   $ 26.49  
Outstanding at September 30, 2026     284     $ 560.92       4,081     $ 53.62  

 

The following table sets forth stock-based compensation expense recognized for the three and nine months ended September 30, 2026 and 2025:

 

   

Three months ended

September 30,

   

Nine months ended

September 30,

 
    2026     2025     2026     2025  
Research and development   $ 31     $ 16     $ 228     $ 573  
Sales and marketing     20       26       68       90  
General and administrative     69       16       567       684  
Total stock-based compensation expense   $ 120     $ 58     $ 863     $ 1,347  

 

At September 30, 2026, there were 19,241 shares available for issuance under the 2022 Plan.

 

Warrants

 

IPO Warrants

 

In April 2022, in association with the Company’s initial public offering, the Company granted to The Benchmark Company, LLC and Valuable Capital Limited warrants to purchase a total of 35 shares of common stock. The warrants were immediately exercisable at an exercise price of $14,000.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO. The fair value of the warrants on the grant date was $7,700.00 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 62.55%, dividend yield of 0%, and risk-free interest rate of 2.92%. The Company recorded the fair value of these warrants of $264 as an issuance cost to additional paid-in capital in 2022. All of the IPO warrants remain outstanding as of September 30, 2026.

 

Registered Offering Warrants

 

In June 2023, in connection with a registered offering of stock, the Company issued warrants to purchase a total of 7,143 shares of common stock (the “Registered Offering Warrants”). The Registered Offering Warrants were exercisable upon issuance and will expire five years from the date of issuance. Per the terms of the Registered Offering Warrants, the exercise price reset on July 16, 2023, to $880.88 per share. The fair value of the Registered Offering Warrants on the grant date of $3,164, or $442.40 per warrant, was calculated using a Monte-Carlo simulation to estimate the final exercise price, which is considered a Level 3 fair value measurement, using as inputs; the starting value of $840.00 per share, the Company’s VWAP on June 16; an assumed daily distribution of returns; a mean daily return of 5.18%; a short-term annual volatility of 100% and a standard deviation of 6.3%. The model used Black-Scholes to then calculate the estimated fair value of the Registered Offering Warrants, using an estimated time to maturity of 4.9 years, a risk-free interest rate of 3.99% and a long-term volatility of 60%. As of September 30, 2026, Registered Offering Warrants to purchase 5,929 shares of common stock remain outstanding.

 

Convertible Note Warrants

 

In November 2023, in connection with the issuance of the Convertible Notes, the Company issued warrants to purchase a total of 161 shares of common stock at an exercise price equal to $543.20 per share. The warrants expire five years from the issuance date. The fair value of the warrants on the grant date was $361.20 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.89%, dividend yield of 0%, and risk-free interest rate of 4.41%. The Company recorded the fair value of these warrants of approximately $58 as an issuance cost to additional paid-in capital in 2023. All of these warrants remain outstanding as of September 30, 2026.

 

13

 

Series A Preferred Stock Warrants

 

On February 20, 2024, in connection with the issuance of Series A Preferred Stock, the Company issued the Series A Preferred Stock Warrants to purchase a total of 1,484 shares of common stock at an exercise price equal to $149.80 per share. The Series A Preferred Stock Warrants are immediately exercisable and expire five years from the date of issuance. The fair value of the Series A Preferred Stock Warrants on the grant date was $170.80 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.24%, dividend yield of 0%, and risk-free interest rate of 4.3%. The Company recorded the fair value of these warrants of $254 to additional paid-in capital in 2024. All of the Series A Preferred Stock Warrants remain outstanding as of September 30, 2026.

 

Series B Preferred Stock Warrants

 

On September 5, 2024, in connection with the issuance of Series B Preferred Stock, the Company issued the Series B Preferred Stock Warrants to purchase a total of 464 shares of common stock at an exercise price equal to $149.65 per share. The Series B Preferred Stock Warrants are immediately exercisable and expire five years from the date of issuance. The fair value of the Series B Preferred Stock Warrants on the grant date was $78.75 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.40%, dividend yield of 0%, and risk-free interest rate of 3.5%. The Company recorded the fair value of these warrants of $37 to additional paid-in capital in 2024. All of the Series B Preferred Stock Warrants remain outstanding as of September 30, 2026.

 

Series C Warrants

 

On March 11, 2025, in connection with the 2025 Warrant Inducement, the Company issued the Series C-1 Warrants to purchase up to an aggregate of 69,878 shares of common stock at an exercise price of $43.75 per share and the Series C-2 Warrants (together with the Series C-1 Warrants, the “Series C Warrants”) to purchase up to an aggregate of 34,939 shares of common stock at an exercise price of $43.75 per share. The Series C Warrants became exercisable on the Approval Date. The Series C-1 Warrants were to expire five years from the Approval Date, and the Series C-2 Warrants were to expire three years from the Approval Date. Pursuant to the 2025 Warrant Inducement, the Company received proceeds, net of financial advisor fees and other transaction expenses, of $2,735.

 

The fair value of the Series C-1 Warrants on the grant date was $33.95 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.40%, dividend yield of 0%, and risk-free interest rate of 4.0%. The fair value of the Series C-2 Warrants on the grant date was $28.00 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 3.00 years, expected volatility of 68.40%, dividend yield of 0%, and risk-free interest rate of 4.0%. The Company recorded the fair value of these warrants to additional paid-in capital in the first quarter of 2025. The Company recorded the excess of the incremental value of the modified Series A New Warrants and Series B New Warrants and the fair value of the Series C Warrants over the cash proceeds from the exercise of the modified Series A New Warrants and Series B New Warrants as equity offering costs. All of the Series C Warrants were cancelled as a part of the 2026 Private Placement.

 

Series D Warrants

 

On March 25, 2025, in connection with a securities purchase agreement, the Company issued warrants to purchase up to 20,958 shares of its common stock at an exercise price of $70.00 per share (the “Series D Warrants”), which were exercisable upon issuance, and will expire five years following the date of issuance. The fair value of the Series D Warrants on the grant date was $95.20 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.40%, dividend yield of 0%, and risk-free interest rate of 4.1%. The Company recorded the fair value of these warrants to additional paid-in capital in the first quarter of 2025. All of the Series D Warrants were cancelled as part of the 2026 Private Placement.

 

Series E Warrants

 

Also on March 25, 2025, in connection with a securities purchase agreement, the Company issued warrants to purchase up to 36,329 shares of its common stock at an exercise price of $70.00 per share (the “Series E Warrants”), which were exercisable upon issuance, and will expire five years following the date of issuance. The fair value of the Series E Warrants on the grant date was $95.20 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.40%, dividend yield of 0%, and risk-free interest rate of 4.1%. The Company recorded the fair value of these warrants to additional paid-in capital in the first quarter of 2025. All of the Series E Warrants were cancelled as part of the 2026 Private Placement.

 

14

 

November 2025 Warrants

 

On November 11, 2025, in connection with entering into securities purchase agreements with certain accredited investors in an at-the-market private investment in public equity financing, the Company issued warrants to purchase 63,380 shares of its common stock at an exercise price of $40.60 per share, with an expiration date of 3 years from the date of issuance (the “November 2025 Warrants”). The fair value of the November 2025 Warrants on the grant date was $15.40 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 3.00 years, expected volatility of 48.80%, dividend yield of 0%, and risk-free interest rate of 3.6%. The Company recorded the fair value of these warrants to additional paid-in capital. All of the November 2025 Warrants remain outstanding as of September 30, 2026.

 

July 2026 Warrants

 

On July 1, 2026, in connection with the 2026 Public Offering, the Company issued the July 2026 Warrants to purchase 378,948 shares of common stock at an exercise price of $13.30 per share, with an expiration date of July 1, 2031. Per the terms of the 2026 Public Offering, the number of shares issuable under the July 2026 Warrants increased to 473,685 on August 10, 2026, due to the Reverse Stock Split. The fair value of the July 2026 Warrants on the grant date was $6.68 per share, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 71.03%, dividend yield of 0%, and risk-free interest rate of 4.2%. The Company evaluated the July 2026 Warrants and determined that, due to the change in the number of warrants related to the Reverse Stock Split, the July 2026 Warrants qualified for liability classification at the time of issuance. See Note 9. July 2026 Warrants to purchase 20,301 shares of common stock were exercised in August 2026. The remaining July 2026 Warrants to purchase 453,384 shares of common stock remain outstanding as of September 30, 2026.

 

Series A Warrants

 

On August 31, 2026, in connection with the 2026 Private Placement, the Company issued the Series A Warrants to purchase 1,058,517 shares of common stock at an exercise price of $5.02 per share, with an expiration date of August 31, 2031. The fair value of the Series A Warrants on the grant date was $2.71 per share, which was calculated using a Monte Carlo simulation with an expected term of 5.00 years, expected volatility of 62.39%, dividend yield of 0%, and risk-free interest rate of 4.5%. The Company evaluated the Series A Warrants and determined that, due to a provision in the agreement which allowed for a change in the exercise price of the Series A Warrants based on contingent uncertain future events, those warrants were not indexed to the Company’s own stock and did not meet the criteria for equity classification and therefore were accounted for as a derivative liability. See Note 9. The Company recorded the fair value of these warrants to derivative liabilities. Series A Warrants to purchase 486,338 shares of common stock were exercised in September 2026. Series A Warrants to purchase the remaining 572,179 shares of common stock were exercised as part of the Inducement Agreement.

 

Series B Warrants

 

On September 14, 2026, in connection with the Inducement Agreement, the Company issued the Series B Warrants to purchase 858,269 shares of common stock at an exercise price of $5.02 per share, with an expiration date of September 14, 2031. The fair value of the Series B Warrants on the grant date was $3.63 per share, which was calculated using a Black-Scholes valuation model with an expected term of 5.00 years, expected volatility of 62.63%, dividend yield of 0%, and risk-free interest rate of 4.8%. The Company recorded the fair value of these warrants to additional paid-in capital in addition to a charge of $3,113 for the inducement consideration, recorded in other income (expense). All of the Series B Warrants remain outstanding as of September 30, 2026.

 

15

 

9. Fair Value

 

Convertible Promissory Notes

 

The Company evaluated the conversion feature of the Convertible Promissory Notes under applicable accounting guidance and concluded that the feature is not indexed to the Company’s own stock and does not meet the criteria for equity classification. Accordingly, the conversion feature was accounted for as an embedded derivative liability.

 

The fair value of the derivative liability at issuance date was $563 as determined using a Monte Carlo simulation model with expected terms of 0.5 and 0.75 years and expected daily volatility of 4.93% and 15,000 simulation paths. The model also incorporated assumptions regarding the optimal behavior of both the holder as it relates to the timing of conversion and the Company as it relates to the exercise of the extension option. The Company used a Monte Carlo simulation due to the presence of path-dependent features, including the use of a multi-day VWAP in determining the conversion price and the Company’s option to extend the maturity date.

 

Due to the use of significant unobservable inputs, the derivative liability was classified as a Level 3 fair value measurement. The derivative was initially recorded at fair value, with a corresponding discount recorded to the carrying value of the Convertible Promissory Notes. The debt discount was amortized to interest expense over the term of the Convertible Promissory Notes using the effective interest method.

 

Subsequent to initial recognition, the derivative liability was remeasured at fair value at each reporting date in accordance with ASC 820, with changes in fair value recognized in earnings within other income (expense) in the condensed statements of operations and comprehensive loss. For the three and nine months ended September 30, 2026, the gain on the change in fair value of the derivative liability was $475 and $563, respectively.

 

The following is a reconciliation of the changes in the fair value of the derivative liability for the nine months ended September 30, 2026:

 

Balance at January 1, 2026   $ —  
Initial recognition of derivative liability     563  
Change in fair value     (563 )
Balance at September 30, 2026   $ —  

 

July 2026 Warrants

 

On July 1, 2026, in connection with a 2026 public offering of stock (see Note 8), the Company issued warrants to purchase 378,948 shares of common stock at an exercise price of $13.30 per share, with an expiration date of July 1, 2031 (the “July 2026 Warrants”). Per the terms of the offering, the number of shares issuable under the July 2026 Warrants increased to 473,685 on August 10, 2026, due to the Reverse Stock Split.

 

The Company evaluated the July 2026 Warrants and determined that, due to the change in the number of warrants related to the Reverse Stock Split, the July 2026 Warrants qualified for liability classification under ASC 480 at the time of issuance. The fair value of the July 2026 Warrants on the grant date of $3,164, or $6.68 per share, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 71.03%, dividend yield of 0%, and risk-free interest rate of 4.2%, was recorded as a warrant liability. The Company incurred $473 in offering costs related to the July 2026 Warrants, which was expensed in other income (expense), net.

 

At the time of the Reverse Stock Split, the July 2026 Warrants were reevaluated, and it was determined that they no longer qualified for liability classification. The change in the fair value of the July 2026 Warrants from the issuance date to the date of the Reverse Stock Split of $1,861 was recorded as a gain in other income (expense). The fair value of the July 2026 Warrants on August 10, 2026 of $1,303 was then reclassified to additional paid-in capital. Warrants to purchase 20,301 shares of common stock were exercised in August 2026. The remaining July 2026 Warrants to purchase 453,384 shares of common stock remain outstanding as of September 30, 2026.

 

16

 

The following is a reconciliation of the changes in the fair value of the July 2026 Warrant liability for the nine months ended September 30, 2026:

 

Balance at January 1, 2026   $ —  
Initial fair value     3,164  
Change in fair value     (1,861 )
Derecognition upon Reverse Stock Split     (1,303 )
Balance at September 30, 2026   $ —  

 

Series A Warrants

 

On August 31, 2026, in connection with a private placement offering (see Note 8), the Company issued warrants to purchase 1,058,517 shares of common stock at an exercise price of $5.02 per share, with an expiration date of August 31, 2031 (the “Series A Warrants”). The Series A Warrants include a provision that, upon the first occurrence of a share combination event, defined in the agreement as a stock split, including a forward split, or a recapitalization or other similar transaction involving common stock, when, at the time of the event the lowest VWAP for the five following days is less than the exercise price, the exercise price will be reset to that lower price. The Company evaluated the Series A Warrants and determined that, due to that provision, the warrants were not indexed to the Company’s own stock and did not meet the criteria for equity classification and therefore were accounted for as a derivative liability.

 

The fair value of the Series A Warrants on the grant date was $2,871, which was calculated using a Monte Carlo simulation model with an expected term of 5.00 years, expected volatility of 62.39%, dividend yield of 0%, and risk-free interest rate of 4.5%. The model also incorporated assumptions regarding the probability of a share combination event occurring within various time frames. The Company used a Monte Carlo simulation due to the presence of path-dependent features, including the use of a multi-day VWAP in determining the potential reset of the exercise price. The Company incurred $384 in offering costs related to the Series A Warrants, which was expensed in other income (expense), net.

 

Due to the use of significant unobservable inputs, the derivative liability was classified as a Level 3 fair value measurement. The Series A Warrants were initially recorded at fair value. In September 2026, all of the Series A Warrants were exercised. The Series A Warrants were remeasured at fair value just prior to the exercise date in accordance with ASC 820, with changes in fair value recognized in earnings within other income (expense) in the condensed statements of operations and comprehensive loss. The fair value of the warrant liability was then derecognized and reclassified to additional paid-in capital. For the three and nine months ended September 30, 2026, the loss on the change in fair value of the Series A Warrants was $1,170.

 

The following is a reconciliation of the changes in the fair value of the Series A Warrant liability for the nine months ended September 30, 2026:

 

Balance at January 1, 2026   $ —  
Initial fair value of Series A Warrants     2,871  
Change in fair value     1,170  
Derecognition upon exercise     (4,041 )
Balance at September 30, 2026   $ —  

 

17

 

10.  Commitments and Contingencies

 

Sales Representative Agreement

 

In April 2020, the Company entered into an Exclusive Sales Representative Agreement, under which the counterparty to the agreement (the “Representative”) received exclusive rights to market, promote, and distribute The Catamaran System in the United States and Puerto Rico. The agreement is for an initial period of five years, and automatically renews for an additional five years unless written notice is given by either party prior to April 27, 2023. The agreement provides for a bonus to be paid to the Representative upon an acquisition or IPO. In May 2021, the Company entered into an Amended and Restated Exclusive Sales Representative Agreement (the “Restated Sales Agreement”). In connection with the amended agreement, the Company paid $500 cash and issued 1,536 shares of common stock to the Representative, for which the Company recorded a combined total of approximately $880 as sales and marketing expense. In addition, the Representative received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering. In October 2021, the Company issued 127 shares of common stock with a fair value of approximately $333 to the Representative in accordance with the anti-dilution provision. In April 2022, the Company issued 893 shares of common stock to the Representative in accordance with the anti-dilution provision, fully satisfying the Company’s obligations.

 

The Restated Sales Agreement restructured the calculation of the bonus paid to the Representative upon an acquisition, removed the bonus payable upon an IPO, and allows the Company to terminate the Restated Sales Agreement as long as the bonus paid to the Representative is at least $6,000.

 

On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the “Termination Agreement”) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative $1,000 in cash; and (ii) the Company agreed to pay the Representative (a) $85 per month during the six months after the date of the Termination Agreement in return for efforts by the Representative to transition operations to the Company, (b) 20% of net sales of the product sold in the United States and Puerto Rico until December 31, 2023 and (c) after December 31, 2023, 10% of net sales until such time as the aggregate amount paid to the Representative under this clause (c) and clause (b) above equal $3,600. In the event of an acquisition of the Company, the Company will pay the Representative $3,600 less previous amounts paid pursuant to clause (b) and clause (c) above. The Company recorded a charge of $1,000 for the payment to the Representative in the fourth quarter of 2022 and expensed the $85 per month charges as incurred over the six-month period. For payments under clause (b) and clause (c) above, the Company originally estimated the fair value of the liability using Level 3 hierarchy inputs based on a Monte Carlo simulation of future revenues with a 25% quarterly estimated standard deviation of growth rates and a 10% probability of dissolution, discounted at an estimated discount rate of 15.4%. Based on the Company’s fair value analysis, a total of $2,611 was charged to sales and marketing expense in the statements of operations and comprehensive loss and recorded as accrued commissions in the balance sheets. For subsequent periods, the Company has used a discounted cash flow model with an estimated discount rate of 15.4% to adjust the liability for actual payments made and updated projections of the timing of future payments.

 

A reconciliation of the liability under clause (b) and clause (c) for the nine months ended September 30, 2026 is as follows:

 

Balance at January 1, 2026   $ 1,836  
Amounts paid during 2026     (299 )
Accretion     80  
Balance at September 30, 2026   $ 1,617  

 

Per the terms of the Termination Agreement, the Company ultimately expects to expense $3,600 under clause (b) and clause (c).

 

Contingent Consideration

 

Contingent consideration relates to royalties and potential payments based on future warrant exercises in conjunction with the SI Acquisition and was calculated using the present value of expected payments based on current revenue, projections of future sales, and other estimates using a discount rate of 14.6%. The fair value of the contingent consideration was determined using Level 3 fair value inputs.

 

A reconciliation of the contingent consideration for the nine months ended September 30, 2026 is as follows:

 

Balance at January 1, 2026   $ 993  
Amounts earned     (177 )
Accretion     198  
Balance at September 30, 2026   $ 1,014  

 

18

 

Credit risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.

 

The Company maintains cash balances at financial institutions located in California. Accounts at these U.S. financial institutions are insured by the Federal Deposit Insurance Corporation up to applicable limits. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

 

The Company grants unsecured credit to its customers based on an evaluation of the customer’s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses.

 

11. Reportable Segment

 

The Company operates in one reportable business segment: the SI Joint segment. The SI Joint segment derives revenue from the sale of The Catamaran System and The SImmetry+ System for treatment of the most common types of SI Joint disorders that cause lower back pain. The accounting policies of the SI Joint segment are the same as those described in the summary of significant accounting principles in Note 2. The chief operating decision maker, which is the Company’s senior executive committee that includes the chief executive officer, the chief financial officer and the chief technology officer, assesses the performance of the SI Joint segment and decides how to allocate resources based on net income which is reported in the statements of operations and comprehensive loss as net loss. The measure of segment assets is reported on the balance sheet as total assets.

 

The chief operating decision maker uses net loss to evaluate income generated from segment assets in deciding whether to continue investing in the segment. Net loss is used to monitor budget versus actual results, to prepare operating budgets, and to assess the performance of the segment and in establishing management compensation. The Company does not have intra-entity sales or transfers.

 

The following table presents selected financial information for the Company’s single business segment for the three and nine months ended September 30, 2026 and 2025:

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Revenue  $1,432   $1,173   $4,090   $2,463 
Less:                    
Cost of sales   482    400    1,381    1,122 
Research and development   804    428    2,234    1,622 
Sales and marketing   1,714    1,538    5,441    4,304 
General and administrative   1,517    2,199    4,753    5,341 
Other expense (income), net   3,554    (53)   4,446    (202)
Net loss  $(6,639)  $(3,339)  $(14,165)  $(9,724)

 

12. Subsequent Event

 

On October 16, 2026, the Company and the investor in the 2026 Private Placement (the “Investor”) entered into a waiver (the “Investor Waiver”), pursuant to which the Investor irrevocably waived the restrictions of Section 4.12 of the securities purchase agreement entered into in connection with the 2026 Private Placement (the “Purchase Agreement”), including Sections 4.12(a) and 4.12(b), solely to the extent necessary to permit the Company to (i) file one or more prospectus supplements increasing the amount of shares of the Company’s common stock that it may offer and sell under the 2026 ATM, and (ii) enter into any amendment to the Sales Agreement related to such increase (See Note 8). The Investor also waived any right to injunctive relief or damages under Section 4.12 of the Purchase Agreement with respect thereto.

 

As consideration for the Investor Waiver, the Company issued to the Investor a Series B common stock purchase warrant (the “New Warrant”) to purchase up to 125,000 shares of Common Stock (the “New Warrant Shares”), which has an exercise price of $5.02 per share and expiration date of September 14, 2031, and is subject to beneficial ownership limitations set forth in the New Warrant. In addition, the Company and the investor agreed to extend the period during which the restrictions set forth in Section 4.12(a) of the Purchase Agreement apply by 15 days, such that such restrictions apply until 75 days following the effective date of the agreement.

 

The Company also agreed to file, as soon as reasonably practicable (and in any event within 60 calendar days of the date of the Investor Waiver), a registration statement on Form S-3 (or other appropriate form) registering the resale by the investor of the New Warrant Shares, to use commercially reasonable efforts to cause such registration statement to become effective within 90 calendar days following the date of the Investor Waiver (or within 120 calendar days in the case of a “full review” by the Securities and Exchange Commission), and to keep such registration statement effective at all times until no holder of the New Warrant owns any New Warrant or associated shares.

 

Also on October 16, 2026, the placement agent waived its rights to prohibit the increase of amount of shares of Common Stock saleable under the Sales Agreement and entered into a respective waiver with the Company (the “Placement Agent Waiver”).

  

As a result of the Investor Waiver and the Placement Agent Waiver, on October 16, 2026, the Company filed a prospectus supplement which increased the amount of shares that are eligible to be sold under the 2026 ATM to shares of common stock having an aggregate offering price of up to $7,176 (which does not include the $2,809 of shares previously sold under the Sales Agreement).

 

19

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and the other information set forth in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 27, 2026. In addition to historical financial information, this discussion and analysis contains forward-looking statements that reflect our plans, estimates and beliefs. You should not place undue reliance on these forward-looking statements, which involve risks and uncertainties. As a result of many factors, including but not limited to those set forth under “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 27, 2026, our actual results may differ materially from those anticipated in these forward-looking statements. See “Cautionary Statement Regarding Forward-Looking Statements.”

 

Overview

 

Tenon Medical, Inc. was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. We are a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. We currently offer two systems to treat a diseased SI Joint. We developed The Catamaran® SI Joint Fusion System (“The Catamaran System”) that offers a novel, less invasive approach to the SI Joint using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. We received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and are currently focused on the U.S. market.

 

In August 2025, we acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System (“The SImmetry+ System”) that treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles-including joint decortication, bone graft placement, and rigid fixation-with the goal of achieving a true biological fusion across the SI Joint.

 

In February 2026, we announced an expansion of our U.S. intellectual property portfolio following receipt of Notices of Allowance from the United States Patent and Trademark Office (USPTO) for multiple patent applications expected to issue in 2026. These newly allowed claims will further strengthen our growing patent portfolio and build upon the 10 patents issued in 2025, including 5 issued by the USPTO and 5 issued internationally.

 

We have incurred net losses since our inception in 2012. As of September 30, 2026, we had an accumulated deficit of approximately $95.5 million. To date, we have financed our operations primarily through public equity offerings, private placements of equity securities, certain debt-related financing arrangements, and sales of our product. We have devoted substantially all of our resources to research and development, regulatory matters and sales and marketing of our product.

 

Recent Developments

 

Bylaws Amendment

 

On June 10, 2026, the Board of Directors approved and adopted Amendment No. 1 (the “Amendment”) to our Bylaws, effective as of that date. The Amendment amended and restated Sections 1.5 and 1.8 of Article I of the Bylaws to change the quorum requirements for meetings of stockholders from a majority to not less than 33 1/3% of the votes entitled to be cast at the meeting, in accordance with Nasdaq Listing Rule 5620, and to provide that holders of a majority of the votes present at a meeting (rather than a majority of all outstanding shares) may determine that voting at meetings of stockholders be conducted by written ballot.

 

Notices from Nasdaq and Reverse Stock Split

 

As previously disclosed, on February 25, 2026, we received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the 30 consecutive business day period between January 9, 2026 and February 24, 2026, our common stock had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we were provided an initial period of 180 calendar days, or until August 24, 2026 (the “Compliance Period”), to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of our common stock needed to be at least $1.00 per share for a minimum of 10 consecutive business days during the Compliance Period. On August 10, 2026 we effected a reverse stock split of our issued and outstanding common stock at a ratio of 1-for-35.

 

On August 24, 2026, due to the Reverse Stock Split, we received written notification from Nasdaq confirming that we had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and this matter is now closed.

 

In addition, on May 21, 2026, we received a written notice from Nasdaq, notifying us that we were no longer in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million. On July 17, 2026, we received a notice from Nasdaq stating that we had regained compliance with the stockholders’ equity rule.

 

20

 

2026 Public Offering

 

On July 1, 2026, we consummated a best efforts public offering (the “2026 Public Offering”) of an aggregate of (i) 157,895 shares of common stock and pre-funded warrants to purchase up to 157,895 shares of common stock and (ii) common stock purchase warrants (the “July 2026 Warrants”) to purchase up to 378,948 shares of common stock. Each share of common stock issued (or pre-funded warrant in lieu thereof) and accompanying July 2026 Warrants were sold at a combined public offering price of $13.30 per share (inclusive of the pre-funded warrant exercise price of $0.035). Per the terms of the 2026 Public Offering, the number of shares issuable under the July 2026 Warrants increased to 473,685 on August 10, 2026, due to the Reverse Stock Split.

 

Each July 2026 Warrant is immediately exercisable for one share of common stock at an exercise price of $13.30 per share and will expire on the fifth anniversary of the initial exercise date. The number of shares of common stock underlying the July 2026 Warrants after adjustment equals 150% of the number of shares of common stock (or pre-funded warrants in lieu thereof) purchased by each purchaser. Each pre-funded warrant is immediately exercisable for one share of common stock at an exercise price of $0.035 per share (or on a cashless basis) and will remain exercisable until the pre-funded warrants are exercised in full.

 

In connection with the 2026 Public Offering, we paid WallachBeth Capital, LLC, the placement agent in the 2026 Public Offering, a cash fee equal to 6.5% of the gross proceeds of the 2026 Public Offering and a non-accountable expense allowance equal to 1% of gross proceeds, reimbursed certain of the placement agent’s expenses, and issued to the placement agent warrants to purchase shares of common stock equal to 3% of the aggregate number of shares sold in the 2026 Public Offering, at an exercise price equal to 120% of the public offering price per share.

 

The proceeds from the 2026 Public Offering, net of placement agent fees and offering expenses were $3,635. We intend to use the net proceeds for partial repayment of outstanding convertible notes, expansion of the commercial footprint of our product portfolio including training clinicians on current procedures, hiring additional direct sales representatives, expansion of our external distribution network, continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes.

 

2026 Private Placement Offering

 

On August 27, 2026, we entered into a securities purchase agreement with an institutional investor for the issuance and sale in a private placement (the “2026 Private Placement”) of pre-funded warrants to purchase up to an aggregate of 597,610 shares of common stock at a purchase price of $5.019 per pre-funded warrant, and warrants to purchase up to an aggregate of 1,058,517 shares of common stock (the “Series A Warrants”). The 2026 Private Placement closed on August 31, 2026. The pre-funded warrants were all exercised in September 2026. Each Series A Warrant has an exercise price of $5.02 per share, is immediately exercisable and will expire five years from issuance.

 

As a part of the 2026 Private Placement, Series C-1 Common Stock Warrants for 69,878 shares at $43.75 per share issued on March 11, 2025, Series C-2 Common Stock Warrants for 34,939 shares at $43.75 per share issued on March 11, 2025, Series D Common Stock Warrants for 20,958 shares at $70.00 per share issued on March 25, 2025, and Series E Common Stock Warrants for 36,329 shares at $70.00 per share issued on March 25, 2025, all of which were owned by the investor, were cancelled. We received gross proceeds of $3,000 from the 2026 Private Placement. WallachBeth Capital LLC acted as our exclusive placement agent and received a cash fee of 7% of the aggregate gross proceeds, plus reimbursement of certain expenses and legal fees. We also entered into a registration rights agreement with the investor providing for the registration of the resale of the shares underlying the pre-funded warrants and Series A Warrants. We used the net proceeds for repayment of certain debt, working capital and general corporate purposes.

 

On September 9, 2026, we announced that we had repaid in full our outstanding original issue discount senior convertible promissory notes, which were issued on March 11, 2026 with an aggregate principal balance of approximately $5.16 million, ahead of their September 11, 2026 maturity date.

 

2026 Inducement Agreement

 

On September 11, 2026, we entered into an inducement offer letter agreement (the “Inducement Agreement”) with the holder of the remaining outstanding Series A Warrants exercisable for up to 572,179 shares of common stock. The holder agreed to exercise the remaining Series A Warrants for cash at the original exercise price of $5.02 per share in consideration for our agreement to issue new unregistered five-year Series B Common Stock Purchase Warrants (“Series B Warrants”) to purchase up to 858,269 shares of common stock (equal to 150% of the shares issued upon exercise of the Series A Warrants) at an exercise price of $5.02 per share. The Series B Warrants will expire five years from the date of issuance. WallachBeth Capital LLC acted as our financial advisor and received a cash fee of 7% of the aggregate proceeds and reimbursement of legal expenses of up to $65. We received gross proceeds of $2,872 from the Inducement Agreement.

 

2026 At-the-Market Offering Program

 

On August 11, 2026, we entered into a Common Stock Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), pursuant to which we may offer and sell, from time to time, shares of our common stock through the Sales Agent in an at-the-market offering. We pay the Sales Agent a commission of 3.0% of the aggregate gross proceeds from each sale. During the quarter ended September 30, 2026, we sold an aggregate of 345,187 shares of common stock under the Sales Agreement for net proceeds of approximately $2,693, and paid the Sales Agent compensation with respect to such sales of approximately $84.

 

21

Product and Intellectual Property Updates

 

On July 2, 2026, we announced that we have received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Catamaran® SI Joint Fusion System. On September 30, 2026, we announced the full commercial launch of our titanium 3D-printed lateral screw as part of The SImmetry+ System, the first component of a next-generation lateral system, following an alpha launch that generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026. On October 15, 2026, we announced that the USPTO had issued eight new patents to us during 2026, bringing our portfolio to 38 issued U.S. patents and 9 international patents, with 31 U.S. and foreign applications pending. On October 28, 2026, we announced the completion of the initial alpha cases with our new Quickstep™ Decorticator for The SImmetry+ System. In the third quarter of 2026, we completed 36 combined physician and distributor trainings.

 

Investor Waiver and Series B Warrant

 

On October 16, 2026, we entered into a waiver with the investor in the 2026 Private Placement, pursuant to which the investor waived certain restrictions in the August 27, 2026 securities purchase agreement solely to permit us to increase the amount of shares that may be sold under the Sales Agreement and to amend the Sales Agreement accordingly. As consideration, we issued the investor a Series B common stock purchase warrant to purchase up to 125,000 shares of common stock at an exercise price of $5.02 per share, expiring September 14, 2031, and agreed to register the resale of the underlying shares and to extend the restrictive period under the purchase agreement by 15 days. WallachBeth Capital LLC also waived its rights to prohibit such increase.

 

As a result of the above-referenced waivers, on October 16, 2026, we filed a prospectus supplement which increased the amount of shares that are eligible to be sold under the 2026 ATM to shares of common stock having an aggregate offering price of up to $7,176 (which does not include the $2,809 of shares previously sold under the Sales Agreement).

 

Officers Appointments

 

Effective October 1, 2026, our Board of Directors (the “Board”) appointed Thomas Batton, Jr. as Chief Revenue Officer, reporting to our Chief Executive Officer and leading our commercial organization. In connection with his appointment, the Board approved a grant to Mr. Batton under the 2022 Plan, of 10,000 restricted stock units, with a grant date of October 1, 2026, vesting as to one-third on October 1, 2027 and as to the remaining two-thirds in four equal semi-annual installments thereafter, subject to Mr. Batton’s continued service.

 

Also effective October 1, 2026, upon approval of the Board, Nathanial Grawey ceased to serve as our Chief Commercial Officer and was appointed as our Chief Strategy and Business Development Officer and his employment agreement with the Company was amended to reflect his new position.

 

Components of Results of Operations

 

Revenue

 

We derive substantially all our revenue from sales of The Catamaran System and The SImmetry+ System to a limited number of clinicians. Revenue from sales of The Catamaran System and The SImmetry+ System fluctuates based on volume of cases (procedures performed), discounts, rebates, and the number of implants used for a particular patient. Similar to other orthopedic companies, our revenue can also fluctuate from quarter to quarter due to a variety of factors, including reimbursement, changes in independent sales representatives and physician activities.

 

Cost of Goods Sold, Gross Profit, and Gross Margin

 

We utilize contract manufacturers for production of The Catamaran System and The SImmetry+ System implants and tray sets. Cost of goods sold consists primarily of costs of the components of The Catamaran System and The SImmetry+ System implants and instruments, overhead related to operations personnel and facility costs, depreciation of tray sets, quality inspection, packaging, scrap and inventory obsolescence, as well as distribution-related expenses such as logistics and shipping costs. We anticipate that certain of our cost of goods sold will increase in absolute dollars as case levels increase.

 

Our gross margins have been and will continue to be affected by a variety of factors, including the cost to have our products manufactured for us, pricing pressure from increasing competition, and the factors described above impacting our revenue.

 

Operating Expenses

 

Our operating expenses consist of sales and marketing, research and development, and general and administrative expenses. Personnel costs are the most significant component of operating expenses and consist of consulting expenses, salaries, sales commissions and other cash and stock-based compensation related expenses. We expect operating expenses to increase in absolute dollars as we continue to invest and grow our business.

 

Sales and Marketing Expenses

 

Sales and marketing expenses primarily consist of salaries, commissions, stock-based compensation expense and travel and entertainment expenses of our sales and market personnel along with commissions paid to our independent distributors. We expect our sales and marketing expenses to increase in absolute dollars with the increased sales of The Catamaran System and The SImmetry+ System resulting in higher commissions and salaries, increased clinician and sales representative training, and the cost to complete our clinical study to gain wider clinician adoption of The Catamaran System. Our sales and marketing expenses may fluctuate from period to period due to the timing of sales and marketing activities related to the commercial activity of our product.

 

Research and Development Expenses

 

Our research and development expenses primarily consist of engineering, product development, regulatory expenses, and consulting services, outside prototyping services, outside research activities, materials, and other costs associated with the development and refinement of our product. Research and development expenses also include related personnel and consultants’ compensation and stock-based compensation expense. We expense research and development costs as they are incurred. We expect research and development expense to increase in absolute dollars as we improve The Catamaran System and The SImmetry+ System, develop new products, add research and development personnel, and undergo clinical activities that may be required for regulatory clearances of future products. 

22

 

General and Administrative Expenses

 

General and administrative expenses primarily consist of salaries, consultants’ compensation, stock-based compensation expense, and other costs for finance, accounting, legal, compliance, and administrative matters. We expect our general and administrative expenses to increase in absolute dollars as we add personnel and information technology infrastructure to support the growth of our business. We also expect to incur additional general and administrative expenses as a result of operating as a public company, including but not limited to: expenses related to compliance with the rules and regulations of the SEC and those of The Nasdaq Stock Market LLC on which our securities are traded; additional insurance expenses; investor relations activities; and other administrative and professional services. While we expect the general and administrative expenses to increase in absolute dollars, we anticipate that it will decrease as a percentage of revenue over time.

 

Gain on Investments, Interest Expense and Other Income (Expense), Net

 

Gain on investments consists of interest income and realized gains and losses from the sale of our investments in money market and other securities. Interest expense is related to borrowings, when applicable. Other income and expenses include miscellaneous amounts, including changes in the fair value of derivative liabilities, issuance costs allocated to warrant liabilities and a charge for warrants issued as inducement consideration.

 

Results of Operations

 

The following table sets forth our results of operations for the periods presented (in thousands):

 

    Three Months Ended September 30,     Nine Months Ended
September 30,
 
Statements of Operations Data:   2026     2025     2026     2025  
Revenue   $ 1,432     $ 1,173     $ 4,090     $ 2,463  
Cost of sales     482       400       1,381       1,122  
Gross profit     950       773       2,709       1,341  
Operating expenses:                                
Research and development     804       428       2,234       1,622  
Sales and marketing     1,714       1,538       5,441       4,304  
General and administrative     1,517       2,199       4,753       5,341  
Total operating expenses     4,035       4,165       12,428       11,267  
Loss from operations     (3,085 )     (3,392 )     (9,719 )     (9,926 )
Other income (expense), net:                                
Gain on investments     43       53       92       202  
Interest expense     (719 )     —       (1,747 )     —  
Other expense, net     (2,878 )     —       (2,791 )     —  
Net loss   $ (6,639 )   $ (3,339 )   $ (14,165 )   $ (9,724 )

 

The following table sets forth our results of operations as a percentage of revenue:

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
Statements of Operations Data:   2026     2025     2026     2025  
Revenue     100 %     100 %     100 %     100 %
Cost of sales     34       34       34       46  
Gross profit     66       66       66       54  
Operating expenses:                                
Research and development     56       36       55       66  
Sales and marketing     120       131       133       175  
General and administrative     106       187       116       217  
Total operating expenses     282       355       304       457  
Loss from operations     (215 )     (289 )     (238 )     (403 )
Other income (expense), net:                                
Gain on investments     3       5       2       8  
Interest expense     (50 )     —       (43 )     —  
Other expense, net     (201 )     —       (68 )     —  
Net loss     (464 )%     (285 )%     (346 )%     (395 )%

 

23

 

Comparison of the Three and Nine Months Ended September 30, 2026 and 2025 (in thousands, except percentages)

 

Revenue, Cost of Goods Sold, Gross Profit, and Gross Margin

 

   Three Months Ended
September 30,
         
   2026   2025   $ Change   % Change 
Revenue  $1,432   $1,173   $259    22%
Cost of sales   482    400    82    21%
Gross profit  $950   $773   $177    23%
Gross profit percentage   66%   66%          

 

   Nine Months Ended
September 30,
         
   2026   2025   $ Change   % Change 
Revenue  $4,090   $2,463   $1,627    66%
Cost of sales   1,381    1,122    259    23%
Gross profit  $2,709   $1,341   $1,368    102%
Gross profit percentage   66%   54%          

 

Revenue. The increase in revenue for both the three and nine months ended September 30, 2026 as compared to 2025 was primarily due to an increase in the number of surgical procedures, including the continued adoption of The SImmetry+ System, which began in August of 2025. The number of surgical procedures was 188 and 142 for the three months ended September 30, 2026 and 2025, respectively, and 540 and 491 for the nine months ended September 30, 2026 and 2025, respectively.

 

Cost of Sales, Gross Profit, and Gross Margin. The change in cost of sales as a percentage of revenue for the nine months ended September 30, 2026 as compared to 2025 was due to the absorption of production overhead costs into our standard cost and operating leverage created due to lower relative fixed costs and increased revenue volume, as well as improved Catamaran per-procedure costs, driven by the 510(k) clearance the Company announced receiving on July 2, 2026, which reclassifies certain instruments to reusable status.

 

Operating Expenses

 

  

Three Months Ended

September 30,

         
   2026   2025   $ Change   % Change 
Research and development  $804   $428   $376    88%
Sales and marketing   1,714    1,538    176    11%
General and administrative   1,517    2,199    (682)   (31)%
Total operating expenses  $4,035   $4,165   $(130)   (3)%

 

  

Nine Months Ended

September 30,

         
   2026   2025   $ Change   % Change 
Research and development  $2,234   $1,622   $612    38%
Sales and marketing   5,441    4,304    1,137    26%
General and administrative   4,753    5,341    (588)   (11)%
Total operating expenses  $12,428   $11,267   $1,161    10%

 

Research and Development Expenses. Research and development expenses for the three months ended September 30, 2026 increased as compared to 2025 primarily due to increased professional fees ($217), payroll and employee expenses ($147) and stock-based compensation ($15). Research and development expenses for the nine months ended September 30, 2026 increased as compared to 2025 primarily due to increased professional fees ($756) and payroll and employee expenses ($179), partially offset by decreased stock-based compensation ($345).

 

Sales and Marketing Expenses. Sales and marketing expenses for the three months ended September 30, 2026 increased as compared to the same period in 2025 primarily due to increased payroll and employee expenses ($179) and commission expenses ($58), partially offset by decreased consulting and professional fees ($99) and stock-based compensation ($5). Sales and marketing expenses for the nine months ended September 30, 2026 increased as compared to the same period in 2025 primarily due to increased payroll and employee expenses ($588), commission expense ($384) and consulting and professional fees ($5), partially offset by decreased stock-based compensation ($22).

 

24

 

General and Administrative Expenses. General and administrative expenses for the three months ended September 30, 2026 decreased as compared to the same period in 2025 primarily due to decreased professional service fees ($778), related primarily to costs associated with acquisition-related activities in 2025, and insurance costs ($16), partially offset by increased payroll and employee expenses ($127) and stock-based compensation ($53). General and administrative expenses for the nine months ended September 30, 2026 decreased as compared to the same period in 2025 primarily due to decreased professional service fees ($791), related primarily to costs associated with acquisition-related activities in 2025, and stock-based compensation ($117), partially offset by increased payroll and employee expenses ($388) and insurance costs ($9).

 

Gain on Investments, Interest Expense and Other Income

 

Gain on investments for the three and nine months ended September 30, 2026 decreased as compared to 2025 due to interest on lower average cash and cash equivalent balances and lower interest rates. Interest expense for the three and nine months ended September 30, 2026 related to interest (including amortization of debt discounts) on our Convertible Promissory Notes. Other income (expense), net for the three months and nine months ended September 30, 2026 related primarily to a charge for warrants issued as inducement consideration ($3,113), issuance costs allocated to liability-classified warrants ($857) and the loss on extinguishment of debt ($74), partially offset by net gains on the change in fair value of our derivative liabilities ($1,166 and $1,254, respectively).

 

Liquidity and Capital Resources

 

As of September 30, 2026, we had cash and cash equivalents of $8.3 million. Since inception, we have financed our operations through private placements of preferred stock, debt financing arrangements, our initial public offering, additional stock offerings and the sale of our products. As of September 30, 2026, we had an accumulated deficit of $95.5 million, and we expect to incur additional losses in the future. We have not achieved positive cash flow from operations to date.

 

Based upon our current operating plan, our existing cash and cash equivalents will not be sufficient to fund our operating expenses and working capital requirements through at least the next 12 months from the date these financial statements were filed. We plan to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. We continue to face challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently expected due to (a) the uncertainty of future revenues; (b) changes we may make to the business that affect ongoing operating expenses; (c) changes we may make in our business strategy; (d) regulatory developments affecting our existing products; (e) changes we may make in our research and development spending plans; and (f) other items affecting our forecasted level of expenditures and use of cash resources.

 

As we attempt to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our sales and marketing efforts, research and development activities, or other operations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, and collaborations. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans. Due to the uncertainty in our ability to raise capital, management believes that there is substantial doubt in our ability to continue as a going concern.

 

Cash Flows (in thousands, except percentages)

 

The following table sets forth the primary sources and uses of cash for each of the periods presented below:

 

    Nine Months Ended
September 30,
             
    2026     2025     $ Change     % Change  
Net cash (used in) provided by:                        
Operating activities   $ (8,106 )   $ (8,521 )   $ 415       (5 )%
Investing activities     (236 )     (831 )     595       (72 )
Financing activities     12,857       6,259       6,598       105  
Net increase (decrease) in cash and cash equivalents   $ 4,515     $ (3,093 )   $ 7,608       (246 )%

 

The decrease in net cash used in operating activities for the nine months ended September 30, 2026 as compared to 2025 was primarily attributable to decreased inventory spending ($993) and accounts receivable ($442), partially offset by our increased net loss adjusted for increased non-cash expenses ($4,161) in addition to decreased accounts payable ($454) and accrued expenses ($344).

 

The decrease in cash used in investing activities for the nine months ended September 30, 2026 as compared to 2025 was due primarily to the purchase of SiVantage assets in 2025 ($750).

 

25

 

Cash provided by financing activities for the nine months ended September 30, 2026 consisted of the gross proceeds from the issuance of common stock and warrants ($7,200), gross proceeds from issuances of common stock ($2,809), gross proceeds from the exercise of warrants ($2,712) and gross proceeds from the exercise of warrants under the Inducement Agreement ($2,872), net of offering costs ($1,910), partially offset by the net repayment of convertible notes ($826). Cash provided by financing activities for the nine months ended September 30, 2025 consisted primarily of gross proceeds from the issuance of common stock from our securities purchase agreements ($4,010) and gross proceeds from the exercise of warrants under the inducement agreement ($3,057), net of total offering costs ($808).

 

Critical Accounting Policies, Significant Judgments, and Use of Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported results of operations during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates under different assumptions or conditions. For the nine months ended September 30, 2026, there were no significant changes to our existing critical accounting policies and estimates from those disclosed in our Annual Report on Form 10-K with the exception of our policy for derivative liabilities which is included in Note 2 to our condensed financial statements.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2026, and December 31, 2025, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

 

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required under Regulation S-K for “smaller reporting companies.”

 

ITEM 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the rules and forms promulgated by the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and President and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Because of the inherent limitations to the effectiveness of any system of disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, with a company have been prevented or detected on a timely basis. Even disclosure controls and procedures determined to be effective can only provide reasonable assurance that their objectives are achieved.

 

As of September 30, 2026, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and President and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) pursuant to Rule 13a-15 of the Exchange Act. Based upon that evaluation, our Chief Executive Officer and President and Chief Financial Officer concluded that our disclosure controls and procedures are not effective at the reasonable assurance level.

 

Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties. Therefore, it is difficult to effectively segregate accounting duties which comprises a material weakness in internal controls. This lack of segregation of duties leads management to conclude that the Company’s disclosure controls and procedures are not effective to give reasonable assurance that the information required to be disclosed in reports that the Company files under the Exchange Act is recorded, processed, summarized and reported as and when required.

 

To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned weaknesses, including, but not limited to, increasing the capacity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across the organization and that we have adequate control over our Exchange Act reporting disclosures.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control procedures over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the fiscal quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

26

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and in item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

(A) Unregistered Sales of Equity Securities

 

Except for the issuances of unregistered securities described in the Current Reports on Form 8-K filed by the Company with the SEC during the quarter ended September 30, 2026, the Company did not issue any equity securities which were not registered under the Securities Act.

 

(B) Use of Proceeds

 

Not applicable.

 

(C) Issuer Purchases of Equity Securities

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

ITEM 5. OTHER INFORMATION

 

During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

27

 

ITEM 6. EXHIBITS

 

EXHIBIT INDEX

 

Exhibit

Number

  Description
3.1   Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to exhibit 3.1 to the Registrant’s Registration Statement on Form S-3 No. 333-271648, filed on May 4, 2023)
3.2   Certificate of Correction to Second Amended and Restated Certificate of Incorporation of the Registrant, filed on October 25, 2023 (incorporated by reference to exhibit 4.2 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
3.3   Amendment to Certificate of Incorporation - Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on November 1, 2023 (incorporated by reference to exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on November 7, 2023)
3.4   Amendment to Certificate of Incorporation - Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on September 4, 2024 (incorporated by reference to exhibit 4.4 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
3.5   Certificate of Designations, Rights and Preferences for Series A Preferred Stock of the Registrant, filed on February 20, 2024 (incorporated by reference to exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on February 22, 2024)
3.6   Amendment to Certificate of Designations, Rights and Preferences for Series A Preferred Stock, filed on September 5, 2024 (incorporated by reference to exhibit 4.6 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
3.7   Certificate of Designations, Rights and Preferences for Series B Preferred Stock, filed on September 5, 2024 (incorporated by reference to exhibit 4.7 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
3.8   Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to the exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on August 10, 2026)
3.9   Bylaws of the Registrant (incorporated by reference to the Registrant’s Registration Statement No. 333-260931, filed on April 20, 2022)
3.10   Amendment No. 1 to the Bylaws of Tenon Medical, Inc. (incorporated by reference to exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on June 11, 2026)
4.1#   Tenon Medical Inc., 2022 Equity Incentive Plan (incorporated by reference to exhibit 10.30 to the Registrant’s Registration Statement S-1/A No. 333-260931, filed on April 20, 2022)
4.2#   Amendment to Tenon Medical, Inc. 2022 Equity Incentive Plan, dated as of July 23, 2024 (incorporated by reference to exhibit 4.10 to the Registrant’s Registration Statement on Form S-8 No. 333-293417, filed on February 12, 2026)
4.3#   Amendment to Tenon Medical, Inc. 2022 Equity Incentive Plan, dated as of September 18, 2025 (incorporated by reference to exhibit 4.10 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
4.4   Form of Representative’s Warrant in connection with the Registrant’s Initial Public Offering (incorporated by reference to exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A No. 333-260931, filed on April 15, 2022)
4.5   Form of publicly traded Warrant issued on June 16, 2023 (incorporated by reference to exhibit 4.1 to the Registrant’s Registration Statement No. 333-272488, filed on June 7, 2023)

 

28

 

4.6   Form of Warrant Agency Agreement between the Company and VStock Transfer, LLC (incorporated by reference to exhibit 4.3 to the Registrant’s Registration Statement No. 333-272488, filed on June 7, 2023)
4.7   Form of Warrant issued to investors on November 21, 2023 (incorporated by reference to exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed on November 28, 2023)
4.8   Form of Warrant issued to investors in the Series A Preferred Stock offering on February 20, 2024 (incorporated by reference to exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed on February 22, 2024)
4.9   Form of Warrant issued to the investors in the Series B Preferred Stock offering (incorporated by reference to exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed on September 6, 2024)
4.10   Form of Series A Warrants issued in September 2024 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on September 16, 2024)
4.11   Form of Series B Warrants issued in September 2024 (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on September 16, 2024)
4.12   Form of Series C-1 Warrant (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on March 12, 2025)
4.13   Form of Series C-2 Warrant (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on March 12, 2025)
4.14   Form of Common Warrants, issued on March 26, 2025 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on March 27, 2025)
4.15   Form of Pre-Funded Warrants issued on March 26, 2025 (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on March 27, 2025)
4.16   Form of Common Warrants, issued on March 27, 2025 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on March 28, 2025)
4.17   Form of Pre-Funded Warrants issued on March 27, 2025 (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on March 28, 2025)
4.18   Form of Common Stock Purchase Warrant, dated November 13, 2025 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on November 17, 2025)
4.19   Form of Senior Convertible Promissory Notes, dated March 11, 2026 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on March 17, 2026)
4.20   Form of Common Warrant issued in connection with the Company’s public offering consummated on July 1, 2026 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on July 2, 2026)
4.21   Form of Pre-Funded Warrant issued in connection with the Company’s public offering consummated on July 1, 2026 (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on July 2, 2026)
4.22   Form of Placement Agent Warrant issued to WallachBeth Capital, LLC in connection with the Company’s public offering consummated on July 1, 2026 (incorporated by reference to exhibit 4.3 to the Registrant’s Current Report on Form 8-K, filed on July 2, 2026)
4.23   Form of Pre-Funded Warrant issued on August 31, 2026 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on August 31, 2026)
4.24   Form of Series A Warrant issued on August 31, 2026 (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on August 31, 2026)
4.25   Form of Series B Warrant issued in connection with the Inducement Agreement dated September 14, 2026 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on September 16, 2026)
10.1#   Employment Agreement dated June 1, 2021 between Steven M. Foster and the Registrant (incorporated by reference to exhibit 10.15 the Registrant’s Registration Statement on Form S-1 No. 333-260931, filed on November 10, 2021)
10.2#   Employment Agreement dated June 1, 2021 between Richard Ginn and the Registrant (incorporated by reference to exhibit 10.16 to the Registrant’s Registration Statement on Form S-1 No. 333-260931, filed on November 10, 2021)

 

29

 

10.3#   Consulting Agreement dated May 7, 2021 by and between Richard Ferrari and the Registrant (incorporated by reference to exhibit 10.17 to the Registrant’s Registration Statement on Form S-1 No. 333-260931, filed on November 10, 2021)
10.4#   Amendment to the Consulting Agreement, dated May 7, 2021, by and between Tenon Medical, Inc. and Richard Ferrari, dated as of May 7, 2026 (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on June 12, 2026)
10.5#   Offer Letter dated as of August 16, 2024, issued by the Company to Kevin Williamson (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on August 27, 2024)
10.6   Form of Securities Purchase Agreement between the Registrant and Lincoln Park Capital Fund, LLC (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on July 28, 2023)
10.7   Form of Securities Purchase Agreement entered into between the Registrant and investors in the Series A Preferred Stock (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 22, 2024)
10.8   Form of Securities Purchase Agreement entered into between the Registrant and investors in the November 2023 Notes (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on November 28, 2023)
10.9   Form of Securities Purchase Agreement entered into between the Registrant and investors in the Series B Preferred Stock financing (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on September 6, 2024)
10.10   Form of Inducement Letter, dated September 16, 2024 (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on September 16, 2024)
10.11   Form of Inducement Letter, dated March 11, 2025 (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 12, 2025)
10.12   Placement Agency Agreement, dated March 25, 2025, by and between Tenon Medical, Inc. and A.G.P./Alliance Global Partners, LLC (incorporated by reference to exhibit 1.1 to the Registrant’s Current Report on Form 8-K, filed on March 27, 2025)
10.13   Form of Securities Purchase Agreement, dated as of March 25, 2025, by and between the Company and the purchasers listed on the signature pages thereto (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 27, 2025)
10.14   Placement Agency Agreement, dated March 25, 2025, by and between Tenon Medical, Inc. and A.G.P./Alliance Global Partners, LLC (incorporated by reference to exhibit 1.1 to the Registrant’s Current Report on Form 8-K, filed on March 28, 2025)
10.15   Form of Securities Purchase Agreement, dated as of March 25, 2025, by and between the Company and the purchasers listed on the signature pages thereto (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 28, 2025)
10.16   Asset Purchase Agreement between Tenon Medical Inc. and SiVantage Inc., dated August 1, 2025 (incorporated by reference to exhibit 2.1 to the Registrant’s Current Report on Form 8-K, filed on August 7, 2025)
10.17   Asset Purchase Agreement between Tenon Medical Inc. and SIMPL Medical, LLC, dated August 1, 2025 (incorporated by reference to exhibit 2.2 to the Registrant’s Current Report on Form 8-K, filed on August 7, 2025)
10.18#   Form of Employment Agreement between Tenon Medical Inc. and Wyatt Geist, dated August 1, 2025 (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on August 7, 2025)

 

30

 

10.19#   Form of Employment Agreement between Tenon Medical Inc. and Nate Grawey, dated August 1, 2025 (incorporated by reference to exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on August 7, 2025)
10.20   Form of Securities Purchase Agreement, dated November 10, 2025, between Tenon Medical Inc. and Purchasers (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on November 17, 2025)
10.21   Form of Securities Purchase Agreement, dated March 11, 2026, between Tenon Medical, Inc. and Purchasers (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 17, 2026)
10.22   Lease Agreement for the Company’s sales facility located in Tampa, Florida, entered into in April 2026 (incorporated by reference to exhibit 10.22 to the Registrant’s Quarterly Report on Form 10-Q, filed on August 13, 2026)
10.23   Form of Securities Purchase Agreement, dated June 29, 2026, by and between Tenon Medical, Inc. and the investors party thereto (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on July 2, 2026)
10.24   Placement Agency Agreement, dated June 29, 2026, by and between Tenon Medical, Inc. and WallachBeth Capital, LLC (incorporated by reference to exhibit 1.1 to the Registrant’s Current Report on Form 8-K, filed on July 2, 2026)
10.25   Sales Agreement, dated August 11, 2026, by and between Tenon Medical, Inc. and A.G.P./Alliance Global Partners  (incorporated by reference to exhibit 1.2 to the Registrant’s Registration Statement on Form S-3, filed on August 11, 2026)
10.26   Placement Agency Agreement, dated August 27, 2026, by and between Tenon Medical, Inc. and WallachBeth Capital LLC (incorporated by reference to exhibit 1.1 to the Registrant’s Current Report on Form 8-K, filed on August 31, 2026)
10.27   Form of Securities Purchase Agreement, dated August 27, 2026, by and between Tenon Medical, Inc. and the purchaser named therein (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on August 31, 2026)
10.28   Form of Registration Rights Agreement, dated August 31, 2026 (incorporated by reference to exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on August 31, 2026)
10.29   Inducement Agreement, dated September 11, 2026 (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on September 16, 2026)
10.30   Financial Advisory Agreement, dated September 11, 2026, by and between Tenon Medical, Inc. and WallachBeth Capital LLC (incorporated by reference to exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on September 16, 2026)
10.31*   Offer Letter Agreement between Tenon Medical Inc. and Thomas Batton, Jr., dated September 9, 2026
10.32*   Amendment to Executive Employment Agreement between Tenon Medical Inc. and Nate Grawey, dated October 1, 2026
19.1   Insider Trading Policy (incorporated by reference to the Registrant’s Annual Report on Form 10-K, filed on March 29, 2024)
21.1   List of Subsidiaries of the Registrant (incorporated by reference to the Registrant’s Registration Statement No. 333-281531, filed on September 9, 2024)
31.1*   Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer and President of Tenon Medical, Inc.
31.2*   Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer of Tenon Medical, Inc.
32.1**   Section 1350 Certification of the President and Chief Executive Officer of Tenon Medical, Inc.
32.2**   Section 1350 Certification of the Chief Financial Officer of Tenon Medical, Inc.
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

#Denotes management compensation plan, agreement or arrangement

 

*Filed herewith

 

**Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

 

31

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TENON MEDICAL, INC.
   
Dated: November 16, 2026 /s/ Steven M. Foster
  Steven M. Foster
 

Chief Executive Officer and President, Director

(Principal Executive Officer)

   
Dated: November 16, 2026 /s/ Kevin Williamson
  Kevin Williamson
 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

32

 

Keep reading